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Chapter 1
Introduction
Dendritic cells play a fundamental role in the initiation of effective immune responses against
microorganisms and tumors. Therefore, these unique cells are very promising therapeutic tools
in order to manipulate the immune system. In cell based immunotherapeutical vaccine strategies
dendritic cells are thought to enhance, control and regulate the immune system to overcome
tumor tolerance to combat cancer.
1.1 Objectives and Concept
This thesis is embedded into a project of the european commission of the 5th frame project
(Project QLK3-2002-01980): ”Development of an immunotherapy for breast cancer based on
dendritic cells by developing and comparing different types of tumor-specific immunogens (Can-
cer Immunotherapy)”. In this context, the goals of this thesis are specified below:
• The development and optimization of a protocol for the standardized and reproducible
generation of fully functional dendritic cells in a clinical scale.
• The transfer of the developed protocol to a fully closed system that is in accordance to
GMP (Good Manufacturing Practice) requirements.
• The production of an effective immunogen based on whole tumor cell information.
• Delivery of the whole tumor cell information to dendritic cells and the evaluation in vitro
using autologous T cell stimulation assays.
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Figure 1.1: The concept of this thesis
• The applicability of the developed system needs to be proven by the comparison of the
dendritic cell protocol using blood from healthy donors with dendritic cells generated
from blood from breast cancer patients.
The concept of this thesis is illustrated in figure 1.1. First of all, the theoretical background
is explained in chapter 2 on page 3 followed by the illustration of the generation of dendritic cells
in chapter 4.1 on page 49. The chapter 4.2 on page 70 is dealing with the apoptosis of monocytes
and their fate during differentiation to dendritic cells. Furthermore, the evaluation of dendritic
cells loaded with whole tumor cell information is described in chapter 4.3 on page 75 by using
the tumor-associated antigen MUC1 as model system. Additionally, the applicability in breast
cancer immunotherapy with the development of a fully closed system and the comparison
of dendritic cells from either blood from healthy donors or breast cancer patients’ blood is
illustrated in chapter 4.4 on page 104.
Indeed, most of the experiments were made possible by cooperation with one partner of the
project, the Breast Cancer Biology Group (Cancer Research UK) at Guy’s Hospital in London,
UK.
Chapter 2
Theoretical Background
2.1 The Components of the Immune System
The immune system, which may be seen as an organ distributed throughout the body, protects
the host against pathogens wherever these may enter. Microorganisms that cause pathology
can be categorized in viruses, bacteria, parasites and fungi. In recognition and elimination of
malignant transformed cells immunity also plays an important role.
The cellular and soluble components of the immune system, which are essential in protection,
recognition and defense to infection, can be divided into four main parts. The first line of an
effective barrier against most microorganisms form the epithelial surfaces (1) of the body,
namely the skin and the mucous membranes. However, microorganisms that do succeed in
crossing the epithelial surfaces have to be recognized by the body. These immune responses
are mediated by leukocytes (2), the white cells of the blood, and soluble components (3) like
antibodies and the complement system. The effective response is launched in the peripheral
lymphoid organs (4), which are distributed throughout the body (Janeway et al., 2001).
The leukocytes (white blood cells) as well as the two other cellular constituents of blood, the
erythrocytes (red blood cells), that transport oxygen, and the thrombocytes (blood platelets),
that trigger blood-clotting in damaged endothelium, derive from the same progenitor cells: the
hematopoietic stem cells in the bone marrow. This hierarchical system of the hematopoiesis,
the blood formation, is a continuous process by which all blood cells are replenished as needed.
Additionally, the equilibrium between produced cells and removal of aging cells is precisely
maintained. From the pluripotent stem cells two more specialized types of stem cells derive, the
common myeloid and the common lymphoid progenitor cells (Encyclopedia Britannica,
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2004; Kondo et al., 2003).
These two specific progenitor lines give rise to different types of leukocytes. The myeloid
lineage develops completely in the bone marrow and can differentiate, accompanied by growth
factors, to erythrocytes, thrombocytes, mast cells, granulocytes (neutrophil, eosinophil and
basophil), monocytes/macrophages and dendritic cells. The lymphoid lineage gives rise to the
lymphocytes, which are distinguished by their sites of differentiation: B lymphocytes mature
in the bone marrow and T lymphocytes and natural killer (NK) cells in the thymus. The
components of the immune system and their function is shown in figure 2.1 on page 5.
Functionally, a natural, innate response and a specific, adaptive immune response can be dis-
tinguished. The innate immunity depends on germline-encoded receptors, which are expressed
on all cells of a particular type, e.g. macrophages or granulocytes, and recognize broad classes of
pathogens to trigger an immediate response. On the other hand, the adaptive immune system
uses a large repertoire of receptors encoded by rearranging genes to recognize a wide variety
of molecular structures. As a consequence, adaptive immunity occurs delayed, because few B
and T lymphocytes specific for the pathogen must undergo clonal expansion and become ef-
fector cells to remove the infectious agent. Thus, the immediate and early immune responses
are mediated by the innate immunity, whereas the late and specific reaction is induced by the
adaptive immunity (Michal, 1999).
The lymphoid organs are organized tissues with large numbers of lymphocytes and can be
divided into the central or primary lymphoid organs, where lymphocytes are generated, and
the peripheral or secondary lymphoid organs, where the adaptive immune response is initiated.
The bone marrow and the thymus are the central lymphoid organs. Within the peripheral
lymphoid organs, a series of distinct compartments can be distinguished: The peripheral lymph
nodes and spleen respond to antigens that have entered the tissues or spread into the blood,
the mucosal immune system (MALT - mucosal associated lymphoid tissue) including the gut-
associated lymphoid tissues (GALT) and specialized structures called Peyer’s patches, the body
cavities and the skin. In each of these compartments specially adapted responses to pathogens
are generated to a particular set of body tissues. Thus, naive lymphocytes are continually
circulating between blood and secondary lymphoid organs until they have encountered their
specific antigen and become activated (Janeway et al., 2001).
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Figure 2.1: The components of the immune system and their activated function
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2.2 Concepts in Immunology
2.2.1 The Adaptive Immune Response
Naive T lymphocytes, mature cells that have not encountered their antigens, are recirculating
through the bloodstream and the peripheral organs, until they are induced to clonal expan-
sion by a matching antigen. Unlike B cells, T cells do not recognize native, soluble proteins
(Koch and Stockinger, 1991). Instead they are activated by their specific antigen in the
form of peptide:MHC complexes on the surface of professional antigen presenting cells (APCs).
However, the peptide:MHC complexes are not sufficient, on their own, for activation of naive
T cells. The stimulation requires the simultaneous delivery of a co-stimulatory signal by the
APCs. Thus, the first signal is mediated through the ligation of the peptide:MHC complex to
the T cell receptor (TCR) and the second subset of co-stimuli are delivered by counter receptors
expressed by the APCs (Acuto and Michel, 2003). The MHC restricted antigen recogni-
tion is illustrated in figure 2.2. Effector T cells can be divided into three functional classes:
Cytotoxic T cells that are activated by MHC class I molecules, T-helper cells type 1 (Th1) and
T-helper cells type 2 (Th2) that are engaged by MHC class II molecules. As only dendritic cells,
macrophages and B cells are able to express both classes of MHC complexes and co-stimulatory
signals on their surface, these cells are known as professional antigen presenting cells. However,
the most potent activators of naive T lymphocytes are mature dendritic cells and thought to
induce all primary T cell responses in vivo (Janeway, 1999). Furthermore they play a crucial
role in the control of immunity, tolerance of self antigens and induction of long-lasting memory,
one of the most important features of the adoptive immunity (Banchereau and Steinman,
1998; Sallusto and Lanzavecchia, 2002).
Antigen Recognition by T cells
T lymphocytes are recognizing antigen:MHC complexes with their T cell receptors (TCRs)
accompanied by a co-receptor, namely CD4 on T-helper cells and CD8 on cytotoxic T cells.
With these co-receptors T lymphocytes are able to distinguish between MHC class I with CD8
and MHC class II molecules with CD4. The TCR is a heterodimer, which is composed of an α-
and a β-chain. A small subpopulation of T cells consists of a γ- and a δ-chain. Thus, two T cell
populations can be divided by their different TCRs: The αβ and the γδ T cells. Every chain is
build of a variable domain, which determines the specificity of the TCR, and a constant domain
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Figure 2.2: T cell recognition of antigens is MHC restricted. The specific T cell receptor (TCR)
recognizes a MHC:antigen complex. Both MHC:peptide complex and co-stimulatory signal is
required for activation of T cells. Cytotoxic T cells (CD8) bind to MHC class I molecules,
T-helper cells (CD4) bind to MHC class II.
near the membrane (figure 2.2). The huge repertoire of T lymphocyte receptors, the variable
receptor chains, are encoded in several pieces and assembled in the developing lymphocyte by
DNA recombination, a mechanism known as gene rearrangement.
The MHC Molecules
Functionally, MHC molecules present antigen derived peptide fragments on their cell surface for
recognition by T cells. Two important properties are essential to make it difficult for pathogens
to evade: The MHC molecules are polygenic, caused by the different MHC class I and class II
genes for different sets of peptide specificity and they are polymorphic, originated by different
variants of each gene (alleles) within the population. This effects directly the range of bound
peptides, the confirmation of the bound peptide and the direct interaction of the peptide:MHC
complex with the TCR (Janeway, 2001).
The MHC class I molecule is a heterodimer of a membrane-spanning α chain, which folds into
three domains (α1, α2 and α3), bound noncovalently to β2-microglobulin. The genes encoding
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for the MHC molecules are located in the major histocompatibility complex on chromosome 6.
In humans the MHC molecules are called Human Leukocyte Antigen (HLA). The class I region
contains the genes encoding for the α-chain of the MHC class I molecules HLA-A, HLA-B and
HLA-C. The genes for the β2-microglobulin are located on chromosome 15 (Michal, 1999).
Two transmembrane chains, α and β, are characteristic for the MHC class II molecule,
whereby each chain forms two additional domains, α1, α2, β1 and β2. The subregions DP, DQ
and DR in the class II region of the major histocompatibility complex contain the genes for the
α- and β-chains of the HLA-DP, HLA-DQ and HLA-DR molecules.
The generation of peptide:MHC class I complexes, which are expressed by all nucleated
cells of the organism, results from a multi-step process, which is illustrated in figure 2.3 on
page 9. Generally, proteasomes freely diffuse in the cytoplasm and degrade proteins to peptides
that range in size from 4 to 20 amino acids. These peptides are transported by an transporter
for antigen processing (TAP), that is resident in the endoplasmatic reticulum (ER), where the
MHC class I molecules are directly loaded. Almost all of the MHC class I associated peptides are
8-11 amino acids in length, typically 9 residues, that fit into the binding groove of the complex.
The chaperones tapasin, calreticulin and ERp60 directly interact with the MHC molecule and
are required for optimal peptide loading. After a successful peptide binding, the MHC class
I molecules are released to the cell surface. Thus, the peptide:MHC class I complex presents
peptides derived from intracellular proteins on the cell surface, which is important for detection
of virus-infected and malignant transformed cells (Yewdell et al., 2003).
MHC class II molecules are synthesized, like MHC class I molecules, in the endoplasmatic
reticulum. To prevent aggregation with peptides in the ER, the invariant chain (Ii) binds
to the peptide-binding groove of MHC class II heterodimers and escorts them from the ER
and Golgi into a vesicle that becomes part of the endosomal pathway (shown in figure 2.4
on page 9). Within this pathway, the Ii is degraded by proteases, leaving the CLIP (class II
associated invariant chain peptide) fragment of Ii in the binding groove of the MHC class II
complex. Engulfed antigens also enter endosomes and are digested into peptides by proteases in
acidic vesicles. These peptides containing vesicles intersect with MHC class II molecules bearing
vesicles to create the MHC class II compartment. The MHC encoded HLA-DM heterodimer
catalyzes the release of CLIP and the binding of degraded antigens, whereby the length of
the bound peptides is not constrained caused by an open binding groove of the MHC class II
molecules. Finally, these peptide:MHC class II molecules are presented on the cell surface. In
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Figure 2.3: MHC class I molecules bind peptides in the endoplasmatic reticulum (ER)
Cytosol
ER
a1
a2
Invariant chainCLIP HLA-DM
b1
b2
Antigen
CLIPproteinsin the ER
Figure 2.4: MHC class II molecules bind peptides generated in acidified endocytic vesicles. In
these vesicles, HLA-DM binds to HLA class II:CLIP complexes for catalyzing the CLIP release
and binding antigenic peptides
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conclusion, the MHC class II pathway presents peptides derived from exogenous antigens on
the surface of APCs (Bryant and Ploegh, 2004; Koch et al., 2000).
The Co-stimulatory Signal
The clonal expansion and acquisition of effector function of naive T cells depend on the strength
of signals received by the T cell receptor and by an array of co-stimulatory signals. The most
prominent receptors on T cells are CD28, which interacts with CD80 and CD86 on APCs, and
CD40 ligand, which can be engaged by CD40. Triggering of the constitutively expressed CD28
on naive T cells by either CD80 or CD86 on APCs provides a potent co-stimulatory signal, which
results in induction of Interleukin-2 (IL-2, the proliferation factor of T cells), expression of the
high affinity α-chain of the IL-2 receptor (CD25) and entry into the cell cycle (Carreno and
Collins, 2002). Induction of CD28 is also critical in delivering survival signals. Furthermore
induction of CD28 enhances the expression of ’second wave’ co-stimulatory receptors, e.g. CD40
ligand, which is critical in class-switched antibody responses and activation of dendritic cells
(Acuto and Michel, 2003).
Surface molecules on cells are grouped systematically in a list named clusters of differen-
tiation (CD). The cell-surface molecule is designated CD followed by a number. However, the
number does not refer to a function or structural element of the corresponding surface protein.
The discussed co-stimulatory molecules belong to different families, e.g. CD28, CD80 and CD86
to the Immunglobulin Superfamily and CD40 and CD40 ligand to the TNF (tumor necrosis
factor) receptor family.
2.2.2 Dendritic Cells
Dendritic cells (DCs) were firstly described by Langerhans in 1868, who found these unique
cells with their long veils in the skin. Nevertheless, it was long speculated about their function
in the immune system. The identification of mouse spleen DCs by Steinman and Cohn
not before 1973 established the knowledge that DCs are the initiators and modulators of the
immune response (Banchereau and Steinmann, 1998; Hart, 1997). As the sentinels in
vivo, they capture antigen efficiently, migrate to the lymphoid organs and stimulate naive T
lymphocytes for clonal expansion, which subsequently migrate to the site of initial infection to
eliminate the infectious agent (figure 2.5). In figure 2.6 on page 11 the activation of CD8+ and
CD4+ T cells by dendritic cells and the involved receptor molecules are illustrated.
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Figure 2.5: In tissue resident dendritic cells efficiently take up antigen and migrate towards
lymph nodes. During this time they get matured and activate T cells in draining lymph nodes.
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Figure 2.6: Dendritic cell stimulation of naive T cells is required for clonal expansion
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The unusual shape gives dendritic cells their name: Many fine veils or dendrites (Greek:
δ%νδρo, dendro: tree) are displayed in isolated cells. This suits the function of efficient uptake
of antigen and presentation to lymphocytes by a high amplification of the surface (Bell et
al., 1999).
Antigen uptake and presentation are the main functions of dendritic cells. For this rea-
son, two defined phenotypes can be distinguished: the immature and the matured. Immature
dendritic cells can efficiently endocytose solid antigens or apoptotic cells by receptor-mediated
phagocytosis (Greek: φαγ%ιν, phagein: eating) or soluble antigens by receptor-independent
macropinocytosis (Greek: piιν%ιν, pinein: drinking). With both pathways dendritic cells can
present the exogenous antigen not only on MHC class II molecules, but also in the context
of MHC class I. This unique feature of DCs is called cross-presentation and consequently the
stimulation of CD8+ cytotoxic T cells cross-priming (Guermonprez et al., 2002). It was
shown on antigens bound to latex beads that these can be processed by both phagocytosis and
macropinocytosis and cross-presented on dendritic cells (Shen et al, 1997; Reis e Sousa
and Germain, 1995). Recently it was suggested that cross-presentation is controlled by the
existence of phagosomal compartments, generated through fusion of the endoplasmatic reticu-
lum with endolysosomal vesicles (Lize´e et al., 2003).
The adaptive immunity starts with the maturation of dendritic cells by direct and indi-
rect activation by pathogens. Dendritic cells directly recognize conserved microbial molecules,
known as pathogen-associated molecular patterns (PAMPs), with so called pattern-recognition
receptors (PRRs). An important group of these PRRs are Toll-like receptors (TLRs), e.g. TLR4
recognizes lipopolysaccharide (LPS), which is contained in the cell walls of gram-negative bac-
teria. Indirectly, DCs are affected by the large series of inflammation associated tissue factors
like cytokines, e.g. Tumor necrosis factor-α (TNF-α), Interferon-γ (IFN-γ) or Prostaglandin
E2 (PGE2). Generally, the maturation process induces the up-regulation of MHC class I and
MHC class II molecules and of co-stimulatory signals like CD80, CD86 and CD40. Furthermore
their ability to take up antigen is lost. Such activation of DCs by microorganisms or tissue
factors is known as polarization, because different types of dendritic cells are induced. This po-
larization results in either type 1, type 2 or regulatory type dendritic cells (illustrated in figure
2.7). These DCs differ in their activation of immune responses. While type 1 DCs induce a cell
mediated immunity, accompanied with IgG1 and IgG3 isotype antibodies and an inflammatory
response, type 2 DCs trigger a humoral immune response with IgG2, IgA and IgE antibodies.
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The regulatory type DCs induce tolerance by a rather immature phenotype (Kapsenberg,
2003).
The maturation process is accompanied by up-regulation of chemokine receptors, namely
CCR7, for homing to the lymph nodes and induction of T cells (figure 2.5 on page 11). The
CCR7 ligands CCL19 and CCL21 play an important role in directing the migration of the
antigen-loaded mature dendritic cells. Chemokines are also involved in attracting naive T and B
cells into the lymph nodes, which results in the contact with the activated DCs. The chemokine
CXCL10, a ligand for CXCR3 on activated T cells, mediates the immune response of T cells
to the site of infection (Luster, 2002).
2.2.3 The T-helper Cell Pathway
Dendritic cells, as potent stimulators of the immune system, can process and present exogenous
antigens in the context of MHC class I and MHC class II and therefore cross-prime CD8+
cytotoxic T lymphocytes (CTL) and stimulate a T-helper cell response (Brossart et al.,
1997, Guermonprez et al., 2002). Thereby DCs bias the development of specific effector
CD4+ T cell subsets, which induce different components of cellular and humoral immunity.
The generation of these polarized T-helper type 1 (Th1) and type 2 (Th2) cells is promoted by
the cytokine environment, the dose of the antigen, strength of antigenic stimulation, duration
of the T cell receptor engagement and the nature and quantity of costimulatory molecules
(Constant and Bottomly, 1997; Kapsenberg, 2003; Langenkamp et al., 2000;
O’Garra and Arai, 2000). However, the T cell stimulation and Th1 and Th2 polarization
require three dendritic cell derived signals. The first signal is the antigen-specific signal, the
second is given by co-stimulatory molecules and the third, the polarizing signal, is mediated by
soluble or membrane-bound factors (Kapsenberg, 2003). The differentiation into Th1 cells is
encouraged by IL-12p70 and IFN-γ (figure 2.8). Interestingly, unlike IFN-γ, which is preventing
the outgrowth of Th2 cells, IL-12p70 has no effect on the Th2 development (Constant and
Bottomly, 1997). In contrast, IL-4 and IL-10 are affecting the priming of Th2 cells (figure
2.9). While IL-4 induces Th2 cell development directly, IL-10 has been reported to suppress
IFN-γ producing Th1 cells (O’Garra and Arai, 2000). The enhancement of CD40 - CD40
ligand interaction is also important to induce either IL-12p70 or IL-4 production. Figure 2.10
on page 16 illustrates the interrelated control mechanism of the Th1 and Th2 pathway.
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immature dendritic cell
type 1maturedendritic cell type 2maturedendritic cell
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Figure 2.7: Immature dendritic cells (DCs) can be polarized by type 1, type 2 and regula-
tory type pathogen-associated molecular patterns (PAMPs) or tissue factors (TFs) to become
different mature effector DCs
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Figure 2.8: T cell stimulation and T-helper cell 1 (Th1) polarization require three dendritic cell
signals: MHC class II:TCR interaction, the co-stimulatory signal and IL-12p70
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Figure 2.9: T cell stimulation and T-helper cell 2 (Th2) polarization require three dendritic cell
signals: MHC class II:TCR interaction, the co-stimulatory signal and IL-4
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Figure 2.10: The T-helper cell type 1 and type 2 (Th1 and Th2) pathway is controlled by
dendritic cells
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2.2.4 Effector Functions of the Immune System
The effector function of the different components of the immune system depends on the kind of
pathogen. There are three classes of effector T cells specialized in dealing with three classes of
pathogen. Cytotoxic T cells (CTLs) induce apoptosis in their target cells that display peptides in
the context of MHC class I on their surface. Th1 and Th2 cells recognize fragments of antigen
bound to MHC class II molecules. Th1 cells activate macrophages to destroy intracellular
microorganisms, activate B cells to produce IgG1 and IgG3 antibodies for opsonization and
release IL-2 and IFN-γ for induction of NK cells and CTLs. On the other hand, Th2 cells direct
an immune response to extracellular pathogens by initiating B cell responses to secrete IgG2,
IgA and IgE isotypes of antibodies. All types of antibody-mediated responses contribute to the
humoral immunity, whereas CTLs, NK cells and macrophages are members of the cell-mediated
immunity (figure 2.10 on page 16).
2.3 Cancer Immunotherapy
2.3.1 Dendritic Cell Vaccines in Cancer Treatment
The previous sections described how adaptive immunity is induced and controlled by dendritic
cells. These immune responses can be launched either to combat invading microorganisms or
to eliminate aberant tissue of a body. The increased understanding of the complicated mech-
anisms in immunobiology resulted in the proposal of the immune surveillance hypothesis by
Burnet in 1970: The body is kept under surveillance by the immune system to detect any aber-
rant cells, which may circumvent control mechanisms and lead to malignancies. The immune
system depends on a number of subsystems, including cell-dependent and humoral immunity,
which eliminate any aberrant tissue (Bremers et al., 2000a, b). However, the immune
surveillance against tumors can fail because of immunological ignorance (Ochsenbein et al.,
1999) or induction of tolerance (Pardoll, 2003). To overcome this tumor escape from im-
mune surveillance (Costello et al., 1999), many new cancer vaccine strategies are based
on the understanding that the nature of dendritic cells is central to the outcome of immune
responses against tumors (Pardoll, 2003). The development of dendritic cell (DC) based
vaccines, their in vitro generation and loading with tumor antigens, may circumvent tumor tol-
erance (McIlroy and Gregoire, 2003). Therefore, immature DCs need to efficiently take
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up exogenous tumor antigens, differentiate to a matured phenotype with up-regulation of MHC
class I, MHC class II and co-stimulatory molecules, migrate towards lymphoid organs to elicit
both a CD4+ and CD8+ T cell response (Schuler et al., 2003). Administering of immature
dendritic cells need to be avoided, as suppressed CTL responses were observed (Dhodapkar
et al., 2001). Furthermore, a cancer vaccine need to prime naive T lymphocytes, boost pre-
existing tumor-specific immunity and overcome tumor-induced inactivation of tumor immunity
(Gunzer and Grabbe, 2001). The principle of a dendritic cell based immunotherapy is shown
in figure 2.11 on page 21. The success of an immunotherapeutical treatment depends on two
major factors: the right tumor associated antigens and the delivery of these antigens to induce
a tumor specific immune response (Gabrilovich, 2002). Therefore, many approaches have
been developed for loading of dendritic cells with tumor associated antigens: Single antigens in
form of peptides are loaded on dendritic cells or whole tumor cell information is delivered as
apoptotic tumor cells, cell lysate, RNA, DNA or tumor cells are fused with dendritic cells.
Peptides
Known tumor associated antigens in form of molecular characterized peptides bound to certain
MHC class I molecules are loaded on DCs that are able to generate a potent immune response.
Thereby anti-tumor responses can be precisely analyzed and monitored by cytotoxic T cell,
cytokine and tetramer analysis. However, this approach is only possible when the tumor epitopes
are known and the peptides match the patients’ MHC class I type (Parmiani et al., 2002).
Both, polymorphism and polygeny contribute to the extreme diversity of MHC molecules
(see chapter 2.2.1). As a result, the peptide binding specificity varies for the different MHC sur-
face proteins. However, it is noteworthy that a large fraction of the human population express
a limited number of predominant alleles. In many of the performed clinical trials HLA-A*0201
positive patients are eligible for treatment, as HLA-A2 is the most common HLA class I speci-
ficity and is found at high frequency in most populations (Browning and Krausa, 1996).
About 25% to 39% of the western European population are positive for HLA-A2 (Imanishi,
1991) and nearly 96% within this group are positive for the HLA-A*0201 allele (Browning
and Krausa, 1996). For this reason a lot of the identified peptides are developed to bind to
the HLA-A*0201 molecule. Nevertheless, utilizing just one TAA to target the heterogeneous
population of tumor cells in vivo may result in tumor escape as not all cancerous cells are
positive for the used TAA or the tumor might alter its expression. Therefore, other approaches
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have been developed to circumvent these disadvantages of HLA matching and usage of distinct
TAAs.
Apoptotic Tumor Cells
Currently, the discussion of which method does result in the best cross-presentation of tumor-
associated epitopes on the surface of dendritic cells led to plenty of approaches using apoptotic
cells for the delivery of whole-tumor cell information. These apoptotic tumor cells are usually
prepared by irradiation and endocytozed by receptor-mediated phagocytosis. This receptor-
mediated uptake and the assumed access of the antigen to the cross-presentation pathway of
dendritic cells were evaluated in different experiments (Jenne et al., 2000; Jenne and
Sauter, 2002; Kotera et al., 2001; Lambert et al., 2001). Nonetheless, no differences
were found to the method of whole-cell lysate (see next paragraph). Thus, the limitations of this
method are the access to viable primary tumor cells that need to be subsequently irradiated.
Whole-cell Lysates
The method is based on DCs loaded with lysates prepared by repeated freezing-thawing cycles of
tumor cells. This mixture of tumor cell associated proteins are processed by DCs and presented
in the form of epitopes able to stimulate T cell responses (Gabrilovich, 2002). Loading
of dendritic cells with whole tumor cell lysate preparations represents a promising method
to utilize all potential known and unknown TAAs and circumvent the disadvantages like the
requirement for known epitopes of the TAAs, HLA-matching of a patient and the necessity of
exact tumor analysis (Schuler et al., 2003; Thumann et al., 2003). Furthermore, this
approach seems to be one of the simplest and is easily to establish in a clinical environment
as no viable tumor cells are needed for a total autologous system. In many in vitro studies it
has been proven that whole tumor cell lysates are efficiently taken up by macropinocytosis and
cross-presented on the surface of dendritic cells evidenced by cytotoxic assays (Bachleitner-
Hofmann, 2002; Berger et al., 2001; Herr et al., 2000; Schnurr et al., 2001;
Vegh et al., 2003; Wen et al., 2001). However, the precise monitoring in clinical settings
is difficult, since the molecular characteristics are unknown.
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RNA
This approach utilizes RNA isolated from tumor cells directly or after amplification via a
RNA-cDNA (Polymerase Chain Reaction (PCR) amplification) -RNA route. Disadvantages
are RNA instability and degradation during preparation, which does affect the expression level
of the specific antigens (Gabrilovich, 2002). Furthermore, this method would be inefficient
if TAAs are used, which are defined by a different, tumor-specific glycostructure. Produced
proteins would be glycosilated by the unaltered machinery of the dendritic cell and therefore
would not represent the malignant glycoform.
DNA Gene Transfer
Another method for loading of DCs is the gene transfer to the antigen presenting cells by
transfection of defined tumor-associated genes or their parts (minigene) (Gabrilovich, 2002).
This approach allows the expression of multiple and different epitopes that match patients’
MHC class I molecules. The limitations of this method are similar to the RNA approach,
especially regarding the glycosilation. Additionally, only known antigens can be used in this
approach.
Fusion of Tumor Cells and DCs
With their article in 2000, Kugler and Stuhler published a startling report of regressions
in renal cell carcinoma using dendritic cell - tumor cell fusion. After the discovery of several ir-
regularities the paper was retracted in 2003. However, a number of studies showed that hybrids,
fusion products of tumor cells with DCs, can elicit a T cell response to tumor cells (Gong et
al., 1997; Gong et al., 2002). The concept of just fusing TAAs presented by tumor cells
and the co-stimulatory signals expressed by DCs seems still quite interesting. Thus, it has still
to be clarified if the generated hybrids are vital and can both process antigen and migrate
towards lymph nodes to elicit an effective T cell response in vivo.
2.3.2 MUC1: A Tumor Associated Antigen in Breast Cancer
The human epithelial mucin MUC1 (CD227) is a large molecular weight type I transmembrane
glycoprotein with a unique extracellular domain build of variable numbers of tandem repeats
of 20 amino acids, each with 5 O-linked glycosilation sites, which is illustrated in figure 2.12 on
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Figure 2.11: The principle of cancer immunotherapy using lysate-pulsed dendritic cells
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Figure 2.12: The structure of the MUC1 core protein with signal sequence, tandem repeat
domain, transmembrane domain and cytoplasmic tail (CT)
22 CHAPTER 2. THEORETICAL BACKGROUND
page 21 (Gendler et al., 1988; Gendler et al., 1990; Lancaster et al., 1990). It
was first identified in human milk (Shimiza et al., 1982), is widely expressed on glandular
epithelial cells (Zotter et al., 1988) and was recently found on cells of the hematopoietic
system like T-cells (Chang et al., 2000; Correa et al., 2003), monocytes and mature
dendritic cells (personal observation). Aberrantly glycosilated MUC1 is overexpressed in the
majority of breast, ovarian (Girling et al., 1989) and other cancer types (Noto et al.,
1997; Zhang et al., 1998). The interest in using the cancer-associated form of MUC1 as
potential target in cancer immunotherapy is reflected by both pre-clinical and clinical studies
(Scholl et al., 2003; Taylor-Papadimitriou et al., 2002).
Epitopes of MUC1
In the cytoplasm proteins are degraded by proteasomes to fragments of 4 to 20 amino acids
and transported by TAP into the endoplasmatic reticulum. These peptides are loaded on MHC
class I molecules, usually 8-11 amino acids in length (see chapter 2.2.1). As MUC1 is aberrantly
O-glycosilated, the pattern of the glycostructure on MUC1 is expected to influence the MHC
class I restricted presentation of epitopes to T lymphocytes (Taylor-Papadimitriou et
al., 2002). Galli-Stampino and colleagues (1997) reported that the glycan-structure
influences the recognition of epitopes by T cells.
In searching for HLA-A*0201 matching epitopes of MUC1, peptides were derived from
the area of the variable tandem repeats and regions flanking the tandem repeat, which are not
affected by changes in the glycosilation. The epitopes F7 (MUC13−21) LLLTVLTVV (Heukamp
et al., 2001) and M1.2 (MUC12−20) LLLLTVLTV (Brossart et al., 1999) are localized
within the signal sequence of MUC1. Especially the M1.2 is of great interest as the frequency
of T cells specific for this epitope were found increased in breast cancer patients compared to
healthy individuals (Taylor-Papadimitriou et al., 2002).
2.4 Generation of Dendritic Cells
The usage of dendritic cells in cancer immunotherapy requires a reproducible generation method
that can be performed under GMP (Good Manufacturing Practice) guidelines and be utilized in
a clinical environment. For the generation of dendritic cells different sources can be used: prolif-
erating CD34+ precursors in blood (Caux et al., 1992) after granulocyte-colony stimulating
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Table 2.1: The generation of dendritic cells as reported in several publications
Name Year Enrichment Serum Feeding Yield∗
Babatz et al. 2003 Magnetic beads 1% YES 12.1%
Dietz et al. 2000 Magnetic beads 2% YES 18.3 ± 6.3%
Felzmann et al. 2003 Magnetic beads NO YES 8.0 ± 3.0%
Meyer-Wentrup et al. 2003 Magnetic beads 1% YES 41.0 ± 4.0%
Motta et al. 2003 Magnetic beads 1% YES 20.7 ± 4.6%
Padley et al. 2001 Magnetic beads 1% YES 30.3 ± 6.4%
Pullarkat et al. 2002 Magnetic beads NO NO 9.2 ± 5.2%
Ratta et al. 2000 Magnetic beads 10% YES 4.8 ± 1.3%
Berger et al. 2002 Attachment 2% YES 19.9 ± 9.6%
Goxe et al. 2000 Elutriation 2% NO 48.3 %
∗Yield: Yield of viable dendritic cells from inoculated monocytes
factor (G-CSF) mobilization (Mackensen et al., 2000), non-proliferating CD14+ monocytes
in peripheral blood after enrichment via magnetic beads (Babatz et al., 2003; Dietz et
al., 2000; Felzmann et al., 2003; Meyer-Wentrup and Burdach, 2003; Motta et
al., 2003; Padley et al., 2000, 2001; Pickl et al., 1996; Pullarkat et al., 2002;
Ratta et al., 2000) or attachment (Araki et al., 2001; Bender et al., 1996; Berger
et al., 2002; Moldenhauer et al., 2003; Morse et al., 1999; Pospisilova et al.,
2002; Romani et al., 1996; Syme et al., 2001; Thurner et al., 1999b; Tuyaerts
et al., 2002) and enrichment of DCs after cultivation of peripheral blood mononuclear cells
(PBMCs) via elutriation (Bernard et al., 1998; Goxe et al., 1999, 2000; Guyre et
al., 2002; Nguyen et al., 2002; Sorg et al., 2003; Spisek et al., 2001; Tazbirkova
et al., 2003; Wong et al., 2001). Rare circulating DCs can also be isolated, but although
patients can be pretreated with Flt3 ligand, the yield of DCs is comparably small (Fong et
al., 2001). While DCs from CD34+ cells require a prolonged culture and special cytokine setup
in order to increase the small number of precursors, monocyte derived dendritic cells are easy to
obtain after enrichment of monocytes by magnetic separation or adherence, followed by differ-
entiation using granulocyte macrophage-colony stimulating factor (GM-CSF) and Interleukin-4
(IL-4). This method developed by Sallusto and Lanzavecchia (1994) and Romani et
al. (1994) is applied widely in experimental protocols (see figure 2.13 on page 24).
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Figure 2.13: The differentiation of monocytes to dendritic cells in a two step process
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Figure 2.14: Surface marker expression on monocytes, immature dendritic cells and matured
dendritic cells during differentiation
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Due to the ease of availability of monocytes, rapidness of fully differentiation to unma-
ture (5 to 6 days) or mature (6 to 8 days) DCs using special maturation stimuli (e.g. TNF-α,
IL-1β, IL-6, PGE2 (Jonuleit et al., 1997), TNF-α, PGE2 (Kalinski et al., 1998) or
lipopolysaccharide (LPS)) and the possibility of avoiding foreign antigens (fetal calf serum),
this protocol was adapted for clinical applications (Thurner et al., 1999a, b). For studies
where DCs are to be cultured ex vivo and then reintroduced to the patient, it is advisable to
avoid fetal calf serum or any kind of foreign antigen due to possible infections and immunogenic-
ity. However, most of the published protocols are using serum in their setup and usually feed
the culture during the differentiation of monocytes to DCs, which does affect the reproduction,
handling and simplicity. In table 2.1 different publications utilizing magnetic bead selection for
monocyte-enrichment are listed and compared to selected reports using attachment or elutri-
ation. Generally, it seems to be quite interesting to determine the cause of the low yield. In
all published reports a common acceptance of the low yield of monocyte-derived dendritic cells
was observed.
Maturation of Dendritic Cells
Monocytes can be differentiated in the presence of GM-CSF and IL-4 to immature dendritic
cells. The second step is the addition of a defined stimulus to induce maturation that result in
a phenotype for effective stimulation of both CD4+ and CD8+ T cells (see chapter 2.2.2). For
the maturation of DCs various stimuli are described, which can induce a matured phenotype,
like lipopolysaccharide (Langenkamp et al., 2000), double-stranded RNA (McGuirk and
Mills, 2002), CpG oligonucleotides (Sparwasser et al., 1998; Weiner et al., 1997),
CD40 ligand (Labeur et al., 1999) and different inflammatory cytokine combinations like TNF-
α, IL-1β, IL-6, PGE2 (Jonuleit et al., 1997) and TNF-α, PGE2 (Kalinski et al., 1998).
These stimuli can be categorized in type 1, type 2 and regulatory type inducing agents that
affect the polarization of DCs (see also chapter 2.2.2). Table 2.2 shows different polarizing factors
and pathogen-associated molecular patterns (PAMPs). However, for clinical applicability the
stimulus should be in full accordance to GMP conditions, should result in reproducible induction
of fully matured DCs and should be usable for large scale production (Thurner et al., 1999a,
b).
The differentiation process of monocytes to fully matured dendritic cells goes along with
changes in the expression of distinct surface molecules (see figure 2.14). The stimulatory
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Table 2.2: Different stimuli that induce maturation and polarization in dendritic cells
Stimulus Type 1 Type 2 Regulatory type
Cytokines IFN-γ, IL-12p70, TNF-β IL-4, IL-5, IL-13 IL-10, TGF-β
Chemokines CCL21
Eicosanoids PGE2
Co-stimulatory factors CD40 ligand
PAMPs LPS, dsRNA, CpG DNA
PAMPs: pathogen-associated molecular patterns, dsRNA: double-stranded RNA, CpG DNA:
oligodeoxynucleotides rich in unmethylated cytosine guanine dinucleotides, TGF: Transforming
growth factor
molecules MHC class I and MHC class II are much stronger expressed on matured DCs.
CD1a, a member of the Immunglobulin superfamily and structurally analog to MHC class
I, serves as molecule for lipid presentation and is typically found on Langerhans cells (Calabi,
1991, 2000). Furthermore the co-stimulatory surface proteins CD40, CD80 and CD86, adhe-
sion molecules like ICAM-1 (Intercellular adhesion molecule) and the maturation marker CD83
are expressed on matured DCs (Zhou and Tedder, 1995a, b, 1996). The receptor for the
complex of LPS and LBP (LPS binding protein), CD14, is not found on both immature and
matured DCs. The chemokine receptor expression, especially CCR7 for the chemotaxis to the
lymph nodes, is up-regulated on fully matured dendritic cells (Luster, 2002).
The expression of these surface proteins are used for the phenotypical analysis of dendritic
cells, whereby only CD83 is distinctively up-regulated on matured DCs.
Chapter 3
Material and Methods
3.1 Solutions
Phosphate Buffered Saline
Table 3.1: Formulation of phosphate buffered saline (PBS), which is an isotonic solution and
not nutritionally complete. The pH was adjusted to 7.3. The solution was autoclaved for 30min.
Distilled water 1L
NaCl 8.00 gL (137mM) Sigma, Deisenhofen, Germany
KCl 0.20 gL (27mM) Sigma, Deisenhofen, Germany
Na2HPO4 1.25
g
L (8mM) Sigma, Deisenhofen, Germany
KH2PO4 0.20
g
L (15mM) Sigma, Deisenhofen, Germany
EDTA Buffer
Table 3.2: Formulation of EDTA buffer. The pH was adjusted to 7.3. The solution was auto-
claved for 30min.
PBS 1L
Na2EDTA · 2H2O 0.74 gL (2mM) Sigma, Deisenhofen, Germany
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Analyzer Buffer
Table 3.3: Formulation of the buffer utilized for glucose, lactate, glutamine and glutamate
analysis. The pH was adjusted to 7.3.
Distilled water 1L
NaCl 5.10 gL (87mM) Sigma, Deisenhofen, Germany
Na2HPO4 5.00
g
L (35mM) Sigma, Deisenhofen, Germany
NaH2PO4 1.00
g
L (8mM) Sigma, Deisenhofen, Germany
Sodium benzoate 0.30 gL (2mM) Sigma, Deisenhofen, Germany
Na2EDTA · 2H2O 0.56 gL (1.5mM) Sigma, Deisenhofen, Germany
Gentamicin 50mgL Sigma, Deisenhofen, Germany
3.2 Lysate from Human Breast Carcinoma Cell Lines
3.2.1 Cultivation of Human Tumor Cell Lines
Table 3.4: Materials for the cultivation of breast carcinoma cell lines
Cell lines MCF-7 ATCC Number: HTB-22
MDA-MB-231 ATCC Number: HTB-26
Medium RPMI 1640 Biochrom, Berlin, Germany
Serum 10% fetal calf serum Biochrom, Berlin, Germany
Versene 0.05% in EDTA / PBS Biochrom, Berlin, Germany
Cultivation Tissue culture flask, 75cm2 NUNC, Wiesbaden, Germany
The epithelial breast carcinoma cell lines used were MCF-7 (intraductal carcinoma,
HLA-A*0201), (Soule et al., 1973) and MDA-MB-231 (adenocarcinoma, HLA-A*0201),
(Cailleau et al., 1974). Both cell lines were derived from carcinomas that metastasized into
the pleural fluid. Cells were cultivated in RPMI 1640 supplemented with 10% heat-inactivated
(56◦C, 30min) fetal calf serum in standard tissue culture flasks (75cm2) at 37◦C and 5% CO2.
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Cells were detached by addition of versene, subcultivated at a ratio of 1:6 and maintained at
low passage number (5 to 20).
3.2.2 Preparation of Tumor Cell Lysate
Table 3.5: Materials for the preparation of tumor cell lysate
Ultrasonic bath U50 Ultrawave, Cardiff, UK
BCA assay Pierce, Perbio Science, Tattenhill, UK
Confluent cells were detached by addition of 3mL of 0.05% versene in 0.02% EDTA solution
and incubated for 10 min at 37◦C. After washing twice with PBS cells were resuspended at
1 · 107 1mL in PBS and frozen at −80◦C. Disruption of cells was carried out by four freeze-thaw
cycles. Cells were thawed by 10min sonication at 4◦C in an ultrasonic bath and subsequently
frozen at −80◦C. The supernatant was collected after centrifugation (1000g / 15min / 20◦C)
and passed through a 0.2µm filter. The protein concentration was determined by a BCA assay
according to the manufacturer’s instructions (Wiechelman et al., 1988).
3.3 Immunoblotting of Prepared Lysate
3.3.1 Lysate Preparation
Table 3.6: Solutions used for lysate preparation
RIPA buffer PBS
0.5% Deoxycholic acid sodiumsalt Sigma, Deisenhofen, Germany
1.0% Nonidate P40 Sigma, Deisenhofen, Germany
0.1% Sodium dodecyl sulfate (SDS) Sigma, Deisenhofen, Germany
Lysate solution 10mL RIPA buffer
1 tablet of complete MIM Roche, Mannheim, Germany
0.1mL Sodium orthovanadate (100mM) Sigma, Deisenhofen, Germany
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Tumor cell lysates were prepared either as described above or otherwise confluent MDA-
MB-231 and MCF-7 cells were harvested, washed twice in PBS and resuspended at 1 ·107 1mL in
lysis buffer (PBS, 0.5% sodium deoxycholate, 1.0% nonidate P40, 0.1% SDS, one tablet of pro-
tease inhibitor (complete MIM) and 0.1mL sodium orthovanadate (100mM) per 10mL of lysis
buffer). The homogenate was passed several times through a fine-gauge needle, incubated for
30min at 4◦C, passed again through a fine-gauge needle, then centrifuged and frozen at −80◦C.
The protein concentration was determined by a BCA assay according to the manufacturer’s
instructions (Wiechelman et al., 1988).
3.3.2 Denaturing Electrophoresis
Table 3.7: Materials and solutions used for SDS-PAGE
Novex Tris-Glycine gel 4-20% Invitrogen, Paisley, UK
Rainbow marker RPN800 Invitrogen, Paisley, UK
Sample buffer (5x) 250mM Tris-HCl, pH 6.8 Sigma, Deisenhofen, Germany
50% Glycerol Sigma, Deisenhofen, Germany
10% SDS Sigma, Deisenhofen, Germany
per 285mL 5x sample buffer:
20mL Mercaptoethanol Sigma, Deisenhofen, Germany
20mL Bromophenolblue
(1% in Trizma Base pH 6.8) Sigma, Deisenhofen, Germany
Running buffer (10x) 30g Tris-HCl Sigma, Deisenhofen, Germany
144g Glycine Sigma, Deisenhofen, Germany
1% SDS Sigma, Deisenhofen, Germany
1L distilled water
To identify the presence of MUC1 protein in the prepared cell lysates, the lysate was
run on SDS-PAGE (sodium dodecyl sulfate - polyacrylamide gel electrophoresis) to sepa-
rate the proteins. Protein samples were boiled for 5min in equal volume of 5x SDS-PAGE
sample buffer (250mM Tris-HCL, pH 6.8, 50% glycerol, 10% SDS, 7% mercaptoethanol and
7% bromophenolblue/Tris-HCL (1% bromophenolblue in Tris-HCL, pH 6.8)). A volume corre-
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sponding to 20µg protein was separated on a 4-20% Tris-Glycine gradient gel with the in table
3.8 listed running conditions.
Table 3.8: Running conditions for SDS-PAGE
Voltage 100V constant
Time 2h
Expected current 30− 40mA (start); 8− 12mA (end)
Temperature 20◦C
3.3.3 Blotting and Detection
Table 3.9: Materials and solutions used for blotting and detection
Hybond-C membrane Nitrocellulose (RPN203E) Amersham, Little Chaltford, UK
Wet blotter Mini Trans-Blot Cell BioRad, Hertfordshire, UK
Blotting buffer 5.3g Trizma Base Sigma, Deisenhofen, Germany
29.0g glycine Sigma, Deisenhofen, Germany
1.0g SDS Sigma, Deisenhofen, Germany
200mL methanol Sigma, Deisenhofen, Germany
800mL distilled water
Detection SuperSignal
Chemoluminescence Kit Pierce, Perbio Science, Tattenhill, UK
X-ray film Fuji, London, UK
The protein was transferred to a Hybond-C membrane using a wet-blotter with the in table
3.10 listed blotting conditions. Blots were blocked for 1h in 5% BSA and 0.1% Tween 20 in
PBS and incubated with HMFG-2 monoclonal antibody supernatant (neat) (Burchell et
al., 1983) overnight at 4◦C. After thorough washing, blots were probed with rabbit anti-
mouse (1:1000) secondary antibody conjugated to HRP for 1h and washed 3 times. The protein
signal was detected using a chemoluminescence kit and exposed to X-ray film.
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Table 3.10: Blotting conditions
Voltage 30V constant
Time 14h
Expected current 150mA (start)
Temperature 4◦C
3.4 Generation of Dendritic Cells
3.4.1 Isolation of CD14+ cells
Table 3.11: Materials and solutions used for the isolation of CD14+ cells
Ficoll-Paque Density: 1.077 gmL Amersham, Uppsala, Sweden
MACS-buffer PBS
0.5% Bovine serum albumine Life Technologies, Karlsruhe, Germany
MACS columns small: MS (up to 2 · 108 cells) Miltenyi, Bergisch Gladbach, Germany
big: LS (up to 2 · 109 cells) Miltenyi, Bergisch Gladbach, Germany
Filter 3M Miltenyi, Bergisch Gladbach, Germany
Micro-beads CD14+ Miltenyi, Bergisch Gladbach, Germany
Magnet MIDI cell sorting kit Miltenyi, Bergisch Gladbach, Germany
Leucosep tubes 50mL Greiner, Solingen, Germany
Tubes 15mL Greiner, Solingen, Germany
Tubes 50mL Greiner, Solingen, Germany
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coat preparations or
blood samples from healthy donors or breast cancer patients by density-gradient centrifugation
on Ficoll-Paque. 15mL of Ficoll-Paque was filled in Leucosep tubes and centrifuged (1000g /
30sec / 20◦C). After that, 15 to 20mL of buffy coat or 30mL of blood samples were overlaid
and centrifuged (1000g / 15min / 20◦C). The plasma (supernatant) was collected for further
processing, the white cell band was transferred into a new 50mL tube and washed twice with
PBS (centrifugation at 400g and 20◦C for 10min). Finally, cells were resuspended in 50mL
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PBS, counted and flowcytometrically analyzed.
CD14+ cells were affinity-purified utilizing the MIDI magnetic cell sorting kit (MACS) (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer’s instructions (Manz
et al., 1995; Thiel et al., 1998). Therefore, PBMCs were incubated with CD14 Micro-
beads (50µL per 108 PBMC) in MACS-buffer (500µL per 108 PBMC) for 15min at 4◦C and
washed once. Labeled cells were passed through a positive selection column and eluted after re-
moval of the column from the magnetic device. For higher purity a second column was used and
the phenotype of cells was assessed by flow cytometry. The step by step protocol is described
below:
• Centrifuge cells (200g / 10min / 20◦C)
• Remove all supernatant
• Labeling: MS (small) Columns: 50µL buffer and 5µL Micro-beads per 107 total cells
• Labeling: LS (big) Columns: 500µL buffer and 50µL Micro-beads per 108 total cells
• Incubate 30min at 4◦C
• Fill up to 2mL (small) or 10mL (big)
• Centrifuge cells (200g / 10min / 20◦C)
• Resuspend in 500µL (small) or 3mL (big) buffer
• Place separation column in the separation unit (with filter)
• Apply 500µL (small) or 3mL (big) buffer
• Pipette labeled cells onto the column
• Wash 3x with 500µL (small) or 3mL (big) buffer
• Apply 2mL (small) or 5mL (big) buffer onto the column and flush the column
• Repeat the separation by using a second column but without filter
• Centrifuge cells (200g / 10min / 20◦C)
• Resuspent cells in 10mL X-VIVO 15
• Counting of cells using CASY 1 and flowcytometric analysis (CD14 / CD3 / HLA-A,B,C)
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3.4.2 Processing of Plasma
Plasma obtained after Ficoll-Paque centrifugation was heat-inactivated at 56◦C for 30min. This
was followed by centrifugation at 1000g and 20◦C for 10min and passing through a 2µm filter.
Finally, the plasma was either utilized directly for freezing of PBMCs or itself frozen at −20◦C
and thawed for usage.
3.4.3 Differentiation of Monocytes to Dendritic Cells
Table 3.12: Materials and solutions used for differentiation of monocytes to immature dendritic
cells
Medium X-VIVO 15 Life Technologies, Karlsruhe, Germany
48 well plates 500µL NUNC, Wiesbaden, Germany
Tissue culture flasks 75cm2 Greiner, Solingen, Germany
Teflon bags 30mL CellGenix, Freiburg, Germany
rhuGM-CSF 400 UmL Leucomax, Norvartis, Nuernberg, Germany
rhuIL-4 2000 UmL R&D, Wiesbaden, Germany
Isolated CD14+ cells were cultured in X-VIVO 15, 400 UmL rhuGM-CSF and 2000
U
mL rhuIL-4
at a cell concentration described in the results section (standard concentration: 1.3 · 106 1mL) in
48 well plates (500µL), tissue culture flasks (75cm2, 30mL) or hydrophobic cell bags (30mL)
at 37◦C and 5% CO2 for 6 days (Bohnenkamp and Noll, 2003).
3.4.4 Maturation of Dendritic Cells
For the maturation of dendritic cells different cytokine stimuli were used: The cytokine cocktails
I or II listed in table 3.13 were added on day 6. For lysate-pulsing of dendritic cells the lysate +
adjuvant combination was supplemented on day 6. The resultant suspension cells were harvested
on day 8 (Bohnenkamp and Noll, 2003).
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Table 3.13: Cytokines and compounds used for the maturation of dendritic cells
Cocktail I TNF-α 1000 UmL R&D, Wiesbaden, Germany
IL-1β 1000 UmL R&D, Wiesbaden, Germany
IL-6 1000 UmL R&D, Wiesbaden, Germany
PGE2 1
µg
mL (0.003µM) Sigma, Deisenhofen, Germany
Cocktail II TNF-α 1000 UmL R&D, Wiesbaden, Germany
PGE2 18
µg
mL (0.051µM) Sigma, Deisenhofen, Germany
Lysate + adjuvant Tumor cell lysate 100 µgmL
TNF-α 1000 UmL R&D, Wiesbaden, Germany
PGE2 1
µg
mL (0.003µM) Sigma, Deisenhofen, Germany
3.4.5 Cryopreservation
For the cryopreservation of PBMCs and dendritic cells heat-inactivated (56◦C for 30min) au-
tologous plasma was used (see section 3.4.2 on page 34). Cells were centrifuged (200g / 10min
/ 20◦C) and resuspended at a cell density of 1 · 107 1mL (PBMCs) and between 1.1 · 106 and
3.5 · 106 1mL (mature dendritic cells) in autologous plasma + 10% DMSO and frozen at −80◦C
in a polysterene box that allowed cooling at nearly 1◦C per minute. For thawing, cells were
transferred into a 50mL tube and suspended in 10mL of icecold X-VIVO 15 (dendritic cells)
or icecold AIM V (PBMCs) medium. After centrifugation (200g / 10min / 20◦C) cells were
resuspended in the corresponding medium at 37◦C.
Table 3.14: Materials and solutions used for the cryopreservation of primary cells
Medium X-VIVO 15 Life Technologies, Karlsruhe, Germany
Medium AIM V Gibco, Carlsbad, CA, USA
Cryovials 1.8mL NUNC, Wiesbaden, Germany
Dimethyl sulfoxide DMSO Sigma, Deisenhofen, Germany
Tubes 50mL Greiner, Solingen, Germany
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3.5 Analytics of Cell Parameter
3.5.1 Cell Counting and Viability
Routinely, for the determination of the cell number and the viability a haemocytometer with
standard trypan blue dye exclusion and a CASY 1 particle counting system (model TT, Schaerfe
System, Reutlingen, Germany) was used.
The cell concentration with a haemocytometer is determined with the term:
number of cells
mL
=
number of cells in 4 quadrants
4
· 104 · dilution factor (3.1)
The viability (trypan blue dye exlusion method) is calcualted by utilizing following formula:
viability =
viable cells
total number of cells
· 100 (3.2)
3.5.2 Flow Cytometric Analysis
Flow cytometry is a useful tool for analyzing certain physical and chemical characteristics of
single cells or particles as they are moving in suspension past a sensing point. The modern flow
cytometer consists of a light source, collection optics, electronics and a computer to translate
generated signals to data. In the used cytometers (FACSCalibur, Becton Dickinson and EPICS
XL Flow Cytometer, Beckman-Coulter) the light source is an argon-laser, which emits coherent
light at a wavelength of 488nm. Scattered and emitted fluorescent light is collected in front of
the light source and at a right angle (90◦) to detect the forward scatter (front) or the side
scattering and fluorescence (right angle) respectively. With flow cytometry different physical
characteristics such as cell size, shape and internal complexity as well as surface molecules,
that can be detected by a fluorescent compound, can be examined. Additionally, many flow
cytometers have the ability to sort, or physically separate, particles from a sample.
The data generated can be displayed using either a linear or a logarithmic scale. The use
of a logarithmic scale is indicated in most biological situations where distributions are skewed
to the right. In this case the effect is to normalize the distribution. Linear scaling is used
when there is not such a broad range of signals, e.g. in DNA analysis. For analysis of surface
molecules antibodies bound to fluorescent dyes were used. The utilized fluorochromes and their
characteristic excitation and emission wavelength is illustrated in table 3.15.
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Table 3.15: Table of fluorochromes used in flow cytometry and their characteristic excitation
and emission wavelength. The channel corresponds to the flow cytometer, in which distinct
emissions are detected.
Channel Sensor∗ [nm] Fluorochrome Excitation [nm] Emission [nm]
FL-1 505-545 Fluorescein
isothiocyanate (FITC) 495 519
FL-2 560-590 R-Phycoerythrin (PE) 480 / 565 578
FL-3 605-635 PE-Cy5 (CyChrome)∗ 480 / 565 / 650 670
PE-Texas Red (ECD) 480 / 565 613
FL-4 ≥660 PE-cyanin 5.1 (PC5) 488 / 565 / 652 670
∗Filters and sensors used in the EPICS XL Flow Cytometer, Beckman-Coulter; Cy-Chrome
was utilized with the FACSCalibur, Becton Dickinson (different sensor and filter array)
Cells were stained with directly conjugated antibodies, which are listed in table 3.16 on page
38. Samples of 40µL of cell suspension (1·105 cells) were incubated for 15min on ice in PBS con-
taining 5% human serum albumin with corresponding antibodies. Cells were then fixed in 0.5%
paraformaldehyde (Sigma, Deisenhofen, Germany). Appropriate isotype controls were used.
Cell lines were analyzed for MUC1 expression with FITC-conjugated HMFG-1 (Burchell et
al., 1983), SM-3 (Burchell et al., 1987) and 12c10 antibodies. Samples were analyzed us-
ing an EPICS XL Flow Cytometer (Beckman-Coulter, High Wycombe, UK) and WinMDA 2.8
software (Scripps Research Institute, La Jolla, CA) or with a FACSCalibur (Becton Dickinson,
Heidelberg, Germany) and CellQuest 3.1 software (Beckton Dickinson).
3.5.3 Apoptosis Analysis
For quantification of monocytes and dendritic cells undergoing early programmed cell death
an annexin V – propidiumiodide apoptosis detection kit (Becton Dickinson, Heidelberg, Ger-
many) was utilized. Analyzed cells were washed once in PBS and resuspended in the provided
binding buffer. Annexin V (FITC-conjugated) and propidiumiodide were added and incubated
for 15min at room temperature in the dark. Immediate flow cytometric analysis was performed
using an EPICS XL Flow Cytometer (Beckman-Coulter, High Wycombe, UK) and WinMDA
2.8 software (Scripps Research Institute, La Jolla, CA). The cell population was selected by
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Table 3.16: Antibodies used for surface protein analysis
Antibody Clone Isotype Fluorochrome Company
reacts with
Isotype control MOPC-21 Mouse IgG1, κ all Becton Dickinson
HLA-A,B,C ω6/32 Mouse IgG1, κ FITC Cancer Research UK
HLA-A*0201 BB7.2 Mouse IgG2b, κ FITC Cancer Research UK
HLA-DR G46-6 Mouse IgG2a, κ CyChrome Becton Dickinson
CD1a HI149 Mouse IgG1, κ CyChrome Becton Dickinson
CD3 UCHT1 Mouse IgG1, κ CyChrome Becton Dickinson
CD4 RPA-T4 Mouse IgG1, κ FITC Becton Dickinson
CD8 RPA-T8 Mouse IgG1, κ PE Becton Dickinson
CD14 M5E2 Mouse IgG2a, κ FITC Becton Dickinson
CD16 3G8 Mouse IgG1, κ FITC Becton Dickinson
CD19 HIB19 Mouse IgG1, κ PE Becton Dickinson
CD25 M-A251 Mouse IgG1, κ PE Becton Dickinson
CD40 5C3 Mouse IgG1, κ FITC Becton Dickinson
CD54 (ICAM-1) HA58 Mouse IgG1, κ PE Becton Dickinson
CD56 B159 Mouse IgG1, κ PE Becton Dickinson
CD69 FN50 Mouse IgG1, κ PE Becton Dickinson
CD71 M-A712 Mouse IgG2a, κ PE Becton Dickinson
CD80 BB1 Mouse IgM, κ FITC, PE Becton Dickinson
CD83 HB15e Mouse IgG1, κ PE Becton Dickinson
CD86 FUN-1 Mouse IgG1, κ FITC, PE Becton Dickinson
CXCR4 12G5 Mouse IgG2a, κ PE Becton Dickinson
CCR7 3D12 Rat IgG2a, κ PE Becton Dickinson
12c10 Mouse IgG1, κ FITC Cancer Research UK
HMFG-1 Mouse IgG1, κ FITC Cancer Research UK
HMFG-2 Mouse IgG1, κ FITC Cancer Research UK
SM-3 Mouse IgG1, κ FITC Cancer Research UK
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forward (FSC) and side scatter (SSC).
3.5.4 Cytospin
With the cytospin method cells were brought up on a slide and subsequently stained with
haematoxylin and eosin (HE), a combination of a basophil (blueish-purple) nuclear stain and
an acidophil (pink) cytoplasmic stain. The detailed protocol is described below:
• Collect cells and adjust to a concentration of 3 · 105 1mL
• Assemble slide filter card (Cytofunnel, Shandon, Cheshire, UK) and sample chamber in
the slide clip and place it in the cytospin head (Cytospin 3, Shandon)
• Pipette 1 drop (by Pasteuer pipette) into sample chamber
• Centrifuge (1500rpm / 2min / 20◦C)
• Leave slides to air dry for 10min
• Fix cells in 100% ethanol (Sigma)
• Leave slides to air dry for 10min
• Put slides into a slide holder and wash once in water
• Stain in haematoxylin (Sigma) for 30sec
• Wash slides for 2min with water
• Stain in eosin (Sigma) for 30sec
• Wash slides for 2min with water
• Dehydrate cells twice in ethanol (Sigma) and twice in xylene (Sigma) for 30sec
• Protection: Coverslips were mounted with Mowiol-DABCO mounting medium
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3.5.5 Scanning Electron Microscopy
Particularly, the Scanning Electron Microscopy (SEM) serves for the representation of surfaces.
Therefore, the object of interest have to fulfill the following conditions: The object needs to be
clean, free of dust and water-free, must not be gassing out in the vacuum and the surface needs
to be electroconductive. For this reason, biological surfaces are sputtered with gold.
The protocol for the preparation of biological specimen is listed below:
• Overlay specimen with a 2.5% glutaraldehyde solution for 1 day
• Wash twice with PBS
• Dehydrate specimen with acetone (increasing percentage from 20% up to 100% for 1h).
Finally, incubate object for 1 day in 100% acetone.
• Critical point drying
• Sputtering with gold
• SEM analysis
3.6 Immunobiological Analysis
3.6.1 Analysis of Endocytosis
The endocytic activity of immature dendritic cells was assessed with FITC-conjugated dextran
(MW=10,000, Molecular Probes, MoBiTec, Go¨ttingen, Germany), Alexa Fluor 488 conjugated
LPS (Molecular Probes) and collagen-I labeled microspheres (2µm, FluoSpheres, Molecular
Probes). For the analysis of dextran (Duperrier et al., 2000) and LPS (Vasselon et
al., 1999) uptake, 2 · 105 dendritic cells were harvested, incubated with 100µL fetal calf
serum for 15min, centrifuged (200g / 10min / 20◦C) and incubated for 1h with 100µL of 1mgmL
dextran or 20 µgmL LPS at 37
◦C (positive) and 0◦C (negative) respectively. Afterwards, cells were
washed three times in ice cold PBS and resuspended in 300µL PBS containing 0.1% trypan
blue (Sigma) to quench fluorescence from the cell surface. The flow cytometrical analysis was
carried out immediately.
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For FluoSpere uptake, 5 · 105 dendritic cells were incubated in PBS supplemented with 5%
FCS with 5 · 106 collagen-I labeled microspheres at 37◦C for 2h and 20h respectively. After
addition of 200µL PBS cells were analyzed directly on a flow cytometer.
3.6.2 Migration of Dendritic Cells
Matured dendritic cells were harvested, washed twice and adjusted to a cell density of 1 · 106
1
mL in X-VIVO 15 medium. The chemotaxis toward chemokines was tested using a transwell
assay (6µm pore size, NUNC, Wiesbaden, Germany). The lower chambers were filled with
500µL medium containing the chemokines CCL19 (MIP-3β, 250 ngmL , R&D), CXCL12 (SDF-1α,
100 ngmL , R&D) or no chemokines (Luft et al., 2002). In the upper chamber 100µL of cell
suspension was inoculated and the assay was incubated at 37◦C and 5% CO2. After 2h cells
in the lower chamber were harvested and counted by a CASY1 particle counter. All migratory
studies were done in triplicate.
3.6.3 Allogeneic T Cell Response
T Cell Proliferation: Flow Cytometric Analysis
Allogeneic responder PBMCs (1 · 106 1mL) with known MHC mismatch were cultured with
matured dendritic cells (1 · 105 1mL (1:10), 5 · 104 1mL (1:20), 2.5 · 104 1mL (1:40) and 1.25 · 104
1
mL (1:80) respectively) in AIM-V medium (Gibco, Carlsbad, CA) for 4 days in 24-well plates
(NUNC, Wiesbaden, Germany) at 37◦C in a humidified 5% CO2 containing atmosphere. On
day 4 proliferation was analyzed by flow cytometer.
Characterization of surface markers involved in activation and proliferation gives insight
into specific cell subsets and T cell responses in the presence of dendritic cells (Nguyen et
al., 2003). Therefore, the expression on T cells of the activation markers CD25 (Interleukin-
2 α-chain) and CD71 (transferrin receptor) was investigated on day 4 of the mixed leukocyte
reaction. Cell samples were stained for CD3 (ECD), CD25 (FITC) and CD71 (PE) respectively.
Corresponding isotype controls were used.
T Cell Proliferation: Counting
Dendritic cells were added to 5 · 105 allogeneic PBMCs at a ratio of 1:10 in 6 well plates and
co-incubated for 4 days in AIM V. After 4 and 7 days 50% of the culture medium were replaced
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and 100 UmL rhuIL-2 (R&D) were added. After 8 days the proliferating T cells were counted,
phenotyped and an Interferon-γ secretion assay was performed (see section 3.7.3 on page 47).
3.6.4 Synthetic Peptides
HLA-A*0201-binding peptides Melan-A / Mart-126−35 A27L ELAGIGILTV (Kawakami et
al., 1994; Romero et al., 1997; Valmori et al., 1998) and influenza A virus matrix58−66
peptide (FLU M1) with the sequence GILGFVFTL (Gotch et al., 1987; Pogue et al.,
1995) were used for in vitro stimulation of T cells. The Pan-HLA-DR binding peptide PADRE
AGVAAWTLKAAA (Alexander et al. (1994), Brossart et al. (1999)) was used to
enhance T-helper cell responses. All peptides were made by Fmoc chemistry with a Syro II
peptide synthesizer (Multisyntech, Witten, Germany). The peptide was analyzed by reversed-
phase liquid chromatography that showed over 90% purity.
3.6.5 MHC Class I Restricted T Cell Response
Table 3.17: Materials used for the MHC class I restricted stimulation of T cells
Medium AIM V Gibco, Carlsbad, CA, USA
rhuIL-7 2400 UmL R&D, Wiesbaden, Germany
rhuIL-2 20 UmL R&D, Wiesbaden, Germany
FLU M1 peptide 40 µgmL / 20
µg
mL Cancer Research UK
Melan-A / Mart-1 peptide 40 µgmL / 20
µg
mL Cancer Research UK
PADRE helper peptide 50 µgmL Cancer Research UK
β2-microglobulin 5
µg
mL Sigma, Deisenhofen, Germany
6 well plates 4mL NUNC, Wiesbaden, Germany
rhuIL-4 R&D, Wiesbaden, Germany
Tissue culture dishes NUNC, Wiesbaden, Germany
PBMCs from buffy coats from healthy donors were obtained and enriched for CD14+ cells
as described (see section 3.4.1 on page 32). The negative fraction was frozen in autologous,
heat-inactivated plasma containing 10% dimethyl sulfoxide (DMSO). The TNF-α and PGE2
matured monocyte-derived dendritic cells were pulsed for 2h at 37◦C with the appropriate
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peptide (40 µgmL), PADRE helper peptide (50
µg
mL) and human β2-microglobulin (5
µg
mL) in serum-
free AIM V medium. The CD14+ depleted fraction of PBMCs was thawed and co-cultured
at a concentration of 1 · 106 1mL with 1 · 105 1mL peptide-pulsed autologous DCs in a volume
of 4mL (triplicates) AIM-V medium and 2400 UmL IL-7 in 6 well plates. After 7 days a second
stimulation was performed. CD4+ cells were depleted by CD4 mAb coated tissue culture dishes.
Enriched cells were centrifuged, resuspended in fresh AIM-V medium containing 20 UmL IL-2,
adjusted to a cell concentration of 1 · 106 1mL and incubated with 5 · 104 1mL DCs, which had
previously been pulsed with appropriate peptide (20 µgmL) and human β2-microglobulin (5
µg
mL).
Feeding of cells was performed every 2nd day by addition of medium supplemented with 20 UmL
IL-2 according to proliferation. Seven days after stimulation T-cells were phenotypically and
functionally analyzed.
3.6.6 Stimulation of Autologous T Cells with Tumor Lysate-pulsed
Dendritic Cells
Table 3.18: Materials utilized for the autologous stimulation of T cells with lysate-pulsed den-
dritic cells
Medium AIM V Gibco, Carlsbad, CA, USA
rhuIL-7 2400 UmL R&D, Wiesbaden, Germany
rhuIL-2 20 UmL R&D, Wiesbaden, Germany
6 well plates 4mL NUNC, Wiesbaden, Germany
Carcinoma cell lysate-pulsed dendritic cells were harvested on day 8 and co-cultured at a
cell density of 1 · 105 1mL with 1 · 106 1mL autologous PBMCs in a volume of 4mL (triplicates)
AIM-V medium and 2400 UmL IL-7 in 6 well plates. Restimulation of PBMCs was performed
weekly with thawed lysate-pulsed dendritic cells at a ratio of 1:20 with fresh medium and 20 µgmL
IL-2. Cells were fed according to proliferation. The cell density of PBMCs was kept between
5 · 105 1mL and 1 · 106 1mL to avoid substrate limitations such as glucose and glutamine (see
also Bohnenkamp et al., 2002). PBMCs were harvested 48h after the 3rd stimulation and
analyzed as described.
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3.6.7 Tetramer Staining
Antigen-specific T cells were identified by using Phycoerythrin-labeled HLA-A*0201 tetramer
complexes (ProImmune, Oxford, UK) folded around the decapeptide analogue Melan-A / Mart-
126−35 A27L ELAGIGILTV, the synthetic analogue of influenza A virus matrix58−66 peptide
GILGFVFTL or the MUC1 specific epitopes F7 (MUC13−21) LLLTVLTVV (Heukamp et
al., 2001) and M1.2 (MUC12−20) LLLLTVLTV (Brossart et al., 1999). To minimize non-
specific staining, each tetramer was titered and used at the lowest concentration that revealed
a positive population for specific cytotoxic T cells. PBMCs or specifically stimulated T cells
were resuspended in PBS containing 5% human serum albumin and incubated with indicated
tetramer for 20min at 20◦C followed by staining with CD8 (PC5) for 15min at 20◦C in the
dark. Cells were washed twice and fixed with 0.5% paraformaldehyde before analyzing by flow
cytometry. A minimum of 50,000 CD8+ events were collected.
3.7 Cytokine Analysis
3.7.1 The Cytometric Bead Array
To analyze the profile of cytokines produced by matured dendritic cells and during autologous
T cell stimulation, supernatants were collected and frozen at −80◦C. The concentrations of
the typical Th1 / Th2 cytokines IFN-γ, TNF-α, IL-2, IL-4, IL-5 and IL-10 respectively were
measured using a cytometric bead array (CBA) kit (Becton Dickinson) for detection of all six
cytokines simultaneously (detection limit: 5 pgmL). In this test, six populations of beads with dis-
tinct fluorescence intensities are coated with corresponding antibodies specific for the proteins
to be investigated and analyzed by flow cytometer (see figure 3.1 on page 45). The human
cytokine capture bead suspension (50µL per test) and detection reagent (50µL per test) were
transferred to assay tubes and incubated with samples and provided standards (50µL per test)
for 3h at 20◦C. After washing with 300µL of provided wash buffer, 300µL of wash buffer was
added and FACS analysis was performed using a FACSCalibur (Becton Dickinson), CellQuest
3.1, CBA software (Becton Dickinson) and Excel (Office 2001, Microsoft, Redmond, USA) ac-
cording to the manufacturer’s instructions. The standard curves for the analyzed cytokines are
shown in figure 3.2 on page 46.
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Figure 3.1: Flowcytometric analysis of different cytokines with the cytometric bead array. Beads
specific for different cytokines (IFN-γ, TNF-α, IL-10, IL-5, IL-4 and IL-2 respectively) can
be distinguished by their fluorescence intensity in the channel FL-3. After incubation with
supernatants, cytokines bind to specific beads and are identified by a specific fluorescent labeled
antibody. The concentration is detected in the channel FL-2.
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Figure 3.2: The standard curves are analyzed with the software Excel (Office 2001, Microsoft)
and the CBA plugin (Becton Dickinson). Measured samples are compared with the standard
curve for calculation of the concentration. The standard curve range for the cytokine concen-
trations is between 5 pgmL and 10,000
pg
mL .
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3.7.2 Enzyme Linked Immunosorbent Assay
Cytokine ELISA kits for rhuGM-CSF (detection limit: 4.7 pgmL), rhuIL-4 (detection limit: 7.8
pg
mL)
and rhuIL-12p70 (detection limit: 7.8 pgmL) were purchased from Becton Dickinson (OptEIA hu-
man ELISA Set, BD PharMingen, Heidelberg, Germany) and were used following the man-
ufacturer’s instructions. The readout of the ELISA-plates was performed using a photometer
(Wallac Victor2, PerkinElmer Life Science, Bad Wildbad, Germany) reader at 450nm with a
correction at 570nm.
3.7.3 Interferon-γ Secretion Assay
For determination of the portion of IFN-γ producing T cells an IFN-γ Cytokine Secretion
Assay (Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to the manufacturer’s
instructions (Scheffold et al., 1995). PBMCs (1 · 106) were washed once, resuspended in
90µL of cold AIM V and incubated with 10µL of the provided cytokine catch reagent for 5min
on ice. After adding of 10mL of AIM V (37◦C), cells were placed in an incubator for 45min
and moved every 5min. Subsequently, the PBMCs were centrifuged (300g / 10min / 4◦C),
resuspended in 90µL of PBS containing 2% bovine serum albumine and incubated with 10µL
of detection antibody for 10min on ice. Cells were washed, stained with antibodies for flow
cytometry (see section 3.5.2 on page 36) and analyzed. In figure 3.3 on page 48 the principle
of the secretion assay is illustrated.
3.8 Analysis of Medium Components
Osmolality was measured using a freezing-point osmometer Osmomat 030 (Gonotec, Berlin,
Germany). Glucose (Ebio compact, Eppendorf, Hamburg, Germany), lactate (YSI 1500L, Yel-
low Springs Instruments, Yellow Springs, USA), glutamine and glutamate (YSI 2700 select,
Yellow Springs Instruments, Yellow Springs, USA) were quantified enzymatically using the in-
dicated automatic analyzer according to the manufacturer’s instructions. Amino acid analysis
was realized using HPLC (Amino Quant 1090 AX, Hewlett Packard, Waldbronn, Germany).
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1. Incubation of the catch reagent
T cellHybrid antibody:cell-specific andcytokine specificbinding sites
2. Cytokine secretion
T cell
3. Detection
T cellAntibody:cytokine-specific,fluorochrome labeled
cell-surfaceprotein
cytokine
Figure 3.3: The principle of the IFN-γ Cytokine Secretion Assay. Hybrid antibodies are used,
which contain a cell-specific and a cytokine-specific binding site. After binding of the antibody
to a common surface molecule, the cells are incubated for 45min to secrete IFN-γ, which binds
to the cytokine-specific binding site. A second fluorochrome labeled antibody detects the bound
cytokine and cells are analyzed by a flow cytometer.
Chapter 4
Results
4.1 The Generation of Dendritic Cells
The aim of the development of a simple and standardized protocol was to obtain a homogenous
population of fully matured dendritic cells in a high yield. For that reason, the disadvantages
of non-uniform culture conditions caused by supplemented serum, non-defined cell densities
and adherence steps need to be circumvented. Furthermore, the need for feeding of cells is to
be avoided to decrease the risk of contamination and labour intensive steps. In this study the
influence of the main important cultivation parameters were investigated to optimize and setup
the serum-free generation of monocyte-derived dendritic cells in the medium X-VIVO 15. Cell
density, GM-CSF and IL-4 concentration, medium components like glucose, lactate and amino
acids were assessed. Moreover, the influence of different maturation stimuli (TNF-α, IL-1β,
IL-6, PGE2 and TNF-α, PGE2) on the maturation status of DCs was examined. During all
optimization steps the requirements for full accordance to GMP (good manufacturing practice)
conditions were considered.
4.1.1 Cell Enrichment and Starting Population of Monocytes
As source of monocytes fresh blood as well as buffy coat preparations from healthy donors
were used. After blood donation (500mL) the blood bag is centrifuged for 16 to 23min at room
temperature at up to 4000g (Deutsches Rotes Kreuz, 2004). Afterwards, three distinct
layers can be distinguished: the plasma layer on the top, the red cell fraction on the bottom
and the intermediate layer, the buffy coat, which contains the white leukocytes of the blood.
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Figure 4.1: Flowcytometric analysis of peripheral blood mononuclear cells after ficoll density
gradient centrifugation. Shown are dot plots of one representative donor. The quadrants of
the dot plot analyzing monocytes (top right) is adjusted due to the higher auto fluorescence
scattering. The isotype control for the center dot plots refers to the blue population.
This intermediate layer was utilized as source of monocytes from peripheral blood mononuclear
cells.
Buffy coat preparations are usually containing not only lymphocytes and monocytes but also
erythrocytes, granulocytes and plasma. For further separation of the lymphocyte and monocyte
fraction a ficoll density gradient centrifugation was done. In this step the cells were divided
by their density and again the intermediate fraction was collected, containing the leukocytes
without granulocytes. In figure 4.1 the flowcytometrical analysis of PBMCs after ficoll density
gradient centrifugation is illustrated. In the forward / sideward scatter (FSC / SSC) dot plot
two different cell populations can be observed, a blue population (R2 = region 2) and a red
population (R1 = region 1). The upper three dot plots represent both regions, which is termed
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Table 4.1: The distribution of cell subpopulations in peripheral blood from one representative
donor (see also figure 4.1)
Whole population Lymphocytes
Subpopulation T cell subset Phenotype Gate 1 [%] Gate 2 [%]
T cells CD3+ 62.1
T-helper cells CD3+CD4+ 33.6∗ 39.1
Cytotoxic T cells CD3+CD8+ 25.1∗ 29.2
Not defined CD3+CD4−CD8− 3.4∗
B cells CD19+ 16.7
NK cells CD56+CD16+ 5.2 5.9
NK cells CD56+CD16− 5.9 6.7
Monocytes CD14+ 7.7
Total∗ 94.6
Not defined 5.4
∗Subpopulation of T cells do not contribute to the calculation of the total cell number.
gate 1 (in this case gate 1 = R1 and R2). By analysis with monoclonal antibodies against
surface molecules specific for T cells (CD3, binds to the T cell receptor), B cells (CD19, an
immunglobulin specific to B cells) and monocytes (CD14, receptor for LPS and LBP complex),
the distribution of the three main components of the mononuclear cells can be demonstrated.
Thereby, the red population, the monocytes (CD14+), can be distinguished by the higher level
of auto fluorescence and the larger size in the forward and sideward scatter. The center dot
plots represent gate 2 (gate 2 = R2). Only the blue region of cells is analyzed in these dot plots
to circumvent interference with the higher level of auto fluorescence of monocytes. In these dot
plots the T cell subpopulations, namely T-helper cells (CD4+, binds to MHC class II molecules)
and cytotoxic T cells (CD8+, binds to MHC class I molecules), and the different natural killer
(NK) cell populations (CD16+CD56+ and CD16−CD56+, CD16: FcγRIII, component of Fc
receptor that binds to different isotypes of antibodies (IgG1, IgG3); CD56: immunglobulin, cell
adhesion molecule) can be distinguished. The three dot plots on the bottom of figure 4.1 show
the isotype controls. In table 4.1 the different cell components of peripheral blood mononuclear
cells are shown.
Different methods of monocyte enrichment are currently discussed in literature (see also
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Table 4.2: Yield of monocytes of 8 different donors after magnetic-bead enrichment
Number of PBMCs Number of monocytes Yield of monocytes
after ficoll after enrichment after enrichment
[-] [-] [%] of PBMCs
Donor 1 6.7·108 4.6·107 6.9
Donor 2 4.9·108 4.2·107 8.6
Donor 3 5.6·108 1.0·108 17.9
Donor 4 8.8·108 8.8·107 10.0
Donor 5 4.7·108 8.8·107 18.7
Donor 6 8.9·108 1.2·108 13.5
Donor 7 7.5·108 1.1·108 14.7
Donor 8 9.0·108 1.1·108 12.2
Mean 7.0·108 8.8·107 12.8
Standard deviation 1.7·108 2.7·107 4.0
chapter 2.4). For the process development of a standardized protocol a homogenous starting
population of monocytes is inevitable for investigation of cytokine influences, medium limi-
tations and metabolite influences. Due to the availability of GMP quality immunomagnetic
beads from Miltenyi (CliniMACS) to isolate CD14+ monocytes (Dzionek et al., 2002), this
method was used in a laboratory setup with Mini- and Midi-MACS magnets and appropriate
columns. The cells were purified using two columns to increase the enrichment efficiency. This
magnetic cell sorting approach was highly effective in isolating CD14+ monocytes from PBMCs
with a yield of 12.8 ± 4.0% (n = 8) (illustrated in table 4.2) and a viability of ≥ 98.0% (Trypan
blue dye exclusion).
In figure 4.2 on page 54 the analysis of magnetic-bead enriched monocytes by forward /
sideward scatter and expression of several surface proteins is shown. As determined by for-
ward side scatter (FSC / SSC) the purity of enriched monocytes was 97.0% of this repre-
sentative donor. Furthermore, the monocytes expressed high levels of MHC class I molecules
(HLA-A,B,C+), medium levels of MHC class II (HLA-DR+) and low levels of CD1a. The co-
stimulatory molecules CD86 (medium expression) and CD40 (weak) were found on their surface.
The adhesion molecule ICAM-1(high), the receptor CD14 (high) and the chemokine receptor
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CXCR4 (medium) were also expressed.
This highly pure population of monocytes were used as source for the development of a
protocol for the generation of dendritic cells.
4.1.2 Cytokine Kinetics
During 6 days monocytes differentiate in the presence of GM-CSF and IL-4 to immature DCs.
Additional two days are required for the maturation of DCs, whereby both cytokines need to
be present to assist the maturation process. Therefore, both GM-CSF and IL-4 must not be
exhausted after 8 days of cultivation, especially if feeding of the culture should be avoided. Thus,
for the cultivation in the presence of these cytokines the concentration should be maintained
or the concentration accordingly adjusted.
Several experiments were done to test the stability and half-life of the mentioned cytokines.
The stability and half-life test was established utilizing triplicates of tissue culture flasks, which
were also used for the generation of DCs. 40 UmL (3,600
pg
mL) GM-CSF and 40
U
mL (227
pg
mL) IL-4
respectively were inoculated in X-VIVO 15 and incubated at 37◦C and 5% CO2 for 30 days.
Samples were taken every 2nd day, frozen and after collection thawed for quantification of GM-
CSF and IL-4. The GM-CSF (Leucomax, Sandoz) concentration remained constant after 30
days. In contrast, the utilized IL-4 was not as stable as the GM-CSF. After 2 days the IL-4
(R&D) decreased to 60% of the initial inoculated cytokine concentration (see figure 4.3 on page
55). Afterwards the remaining IL-4 concentration showed further decay following a first order
reaction, which is demonstrated in figure 4.4 on page 55. The rate constant was determined to
k = 0.031d and the half-life to t 12 =
ln 2
k = 23d. A possible mechanism of the strong decrease in
IL-4 concentration after 2 days may be the attachment of the cytokine to the positively charged
surface of the tissue culture flask. Consequently, for the calculation of the rate constant only
values between the 2nd and the 30th day were used.
4.1.3 Influence of Different Cell Densities on Yield and Maturation
of DCs
To setup and optimize the protocol for the generation of dendritic cells, the influence of different
cell densities on the consumption and accumulation of medium components such as glucose, lac-
tate, amino acids and supplemented cytokines was investigated. The goal of these experiments
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Figure 4.2: Flowcytometric analysis of monocytes after magnetic-bead enrichment (MACS).
Shown is one representative donor. Outlined histograms indicate isotype controls, histograms
correspond to gated cells
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Figure 4.3: The concentration of IL-4 during the incubation for 30 days. The cytokine concen-
tration was analyzed flowcytometrically by an cytometric bead array.
Figure 4.4: The determination of the rate constant k of the first order reaction; ln (c/c0) is
plotted against time; the slope gives k.
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was to show that a batch cultivation strategy (without feeding) can be used for the differentia-
tion of monocytes to dendritic cells. However, it has to be proven that the metabolism of these
non proliferating cells does not enrich metabolites toxic for the differentiation. The parameters
of performed experiments are shown in table 4.3.
Table 4.3: The parameters of the experiments to test the influence of different cell densities
Cell densities 3.3 · 105, 6.6 · 105, 1.3 · 106, 2.6 · 106 1mL
Donors three
Cultivation system 48 well plates, 500µL volume
Medium X-VIVO 15
GM-CSF 800 UmL
IL-4 500 UmL
Maturation stimulus TNF-α (1000 UmL), IL-1β (1000
U
mL),
IL-6 (1000 UmL), PGE2 (1
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
In different experiments 3.3·105, 6.6·105, 1.3·106 and 2.6·106 1mL monocytes were inoculated
in X-VIVO 15 supplemented with 800 UmL GM-CSF and 500
U
mL IL-4 (Feuerstein et al.,
2000) and incubated for 6 days without feeding. The maturation cytokines TNF-α (1000 UmL),
IL-1β (1000 UmL), IL-6 (1000
U
mL) and PGE2 (1
µg
mL) (Jonuleit et al., 1997) were added on
day 6 and incubated for further two days.
However, as described in the previous section 4.1.2, the cytokine IL-4 might attach to the
positive charged surface of the tissue culture flasks. For that reason both GM-CSF and IL-4
were added two hours after the inoculation of the cells. Monocytes are strongly plastic adherent,
which results in the occupation of the bottom of the flask leaving less space for the binding of
the IL-4. This finding was further assured by the fact that inoculation of GM-CSF and IL-4
directly with cells resulted in lower yield of dendritic cells compared to the latter method.
After 6 days of cultivation partly non-adherent dendritic cells could be observed, which did
not express CD83, a marker of mature dendritic cells (Zhou and Tedder, 1995). The mat-
uration stimulus added for two additional days induced the expression of CD83 and increased
the surface proteins CD80 and CD86 as well as HLA-DR (MHC class II). These non-adherent
dendritic cells with many motile veils showed the typical pattern of mature DCs, which is il-
4.1. THE GENERATION OF DENDRITIC CELLS 57
Figure 4.5: Influence of different cell densities on yield after generation of DCs. Monocytes were
enriched via immunomagnetic beads, inoculated at specified cell densities and differentiated
with 800 UmL GM-CSF and 500
U
mL IL-4. For maturation a cytokine cocktail consisting of TNF-
α (1000 UmL), IL-1β (1000
U
mL), IL-6 (1000
U
mL) and PGE2 (1
µg
mL) was used. The data represent
the mean ± SD (standard deviation) of triplicates from a single donor. The relative yield was
calculated in relation to 1.3 · 106 1mL . From (Bohnenkamp and Noll, 2003)
lustrated in figure 4.6 on page 58. The size of the cells increased from an average of 10µm
(monocytes) to 16µm (DCs), which was determined by the CASY 1 particle counter.
The yield (as defined by size of cells, morphology and surface antigen expression) of matured
DCs was similar for the cultures initially inoculated with 3.3 · 105, 6.6 · 105 and 1.3 · 106 1mL
monocytes and about 25% lower for the highest inoculated cell density (see figure 4.5). All
cell densities except for the 2.6 · 106 1mL showed the typical mature DC phenotype with high
expression of HLA-DR (MHC class II), CD80, CD83 and CD86, which is illustrated in figure
4.7. The DCs differentiated and matured from 2.6 · 106 1mL monocytes expressed reduced HLA-
DR, CD80, CD83 and CD86 antigens. The HLA-DR / CD80 and HLA-DR / CD83 dot plots
for 6.6 · 105 and 1.3 · 106 1mL showed two distinct populations of dendritic cells: a population
with higher HLA-DR / CD80 and HLA-DR / CD83 expression and a lower one, which may be
caused by a different maturation status. Especially for the HLA-DR / CD80 dot plot for the
cell density of 1.3 · 106 1mL this observation was obvious. Lower HLA-DR expression seems to
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Figure 4.6: Cytospins of dendritic cells after the cultivation of 8 days. After centrifugation on a
cytofunnel, cells were stained with haematoxylin and eosin. Photographs were taken at a 100x
magnification with a Fuji Finepix S2 and subsequently edited in contrast and color for original
reproduction.
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Figure 4.7: Phenotype of DCs generated with in table 4.3 specified cultivation parameters.
HLA-DR / CD80, HLA-DR / CD86 and HLA-DR / CD83 dot plots are shown for different
cell densities (3.3 · 105, 6.6 · 105, 1.3 · 106 and 2.6 · 106 1mL respectively). Decreased levels of
CD80, CD83 and CD86 were expressed for the highest cell density, HLA-DR / CD80 and HLA-
DR /CD83 dot plots for 6.6 · 105 and 1.3 · 106 1mL featured a higher and a lower expressing
population. The data shown are from one representative experiment out of 3 performed. From
(Bohnenkamp and Noll, 2003)
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Figure 4.8: Glucose and lactate analysis on day 8 after generation of DCs. Shown is one repre-
sentative experiment out of three. From (Bohnenkamp and Noll, 2003)
Figure 4.9: Glutamine and glutamate analysis on day 8 after generation of DCs. Shown is one
representative experiment out of three.
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correlate with a decrease in CD80 surface antigen expression. The mean fluorescent intensity
as an indicator for the level of expression of CD40 decreased about 50% with the highest cell
density (data not shown). No differences in expression of CD1a were observed (data not shown).
The medium components were also analyzed, whereby an increase in lactate concentra-
tion at the highest cell density at ≥ 25mmolL (see figure 4.8 on page 60) was found, which
caused a decreased culture pH and might be responsible for the lower yield. Accumulation of
metabolic products like lactate produces an acidic environment and therefore inhibits prolifer-
ation (Bohnenkamp et al., 2002, Patel et al., 2000). The glucose concentration in all
experiments remains above limiting levels. Amino acid analysis demonstrated no limitation for
glutamine and serine. The highest glutamate concentration was 1.4mmolL , which is illustrated in
figure 4.9 on page 60.
An ELISA for GM-CSF and IL-4 showed no limitation for GM-CSF (GM-CSF residual
content: 3.3 · 105 1mL : 780 UmL , 6.6 · 105 1mL : 720 UmL , 1.3 · 106 1mL : 450 UmL and 2.6 · 106 1mL :
500 UmL respectively) but IL-4 was limiting (detection limit: 7.8
pg
mL) (data not shown), which
might explain the non-homogenous DC population especially for the 6.6 · 105 and 1.3 · 106 1mL
inoculated monocytes.
Due to a cost-effective utilization of the cultivation system in terms of highest yield of
matured dendritic cells per volume, all further experiments were performed at a cell density of
1.3 · 106 1mL inoculated monocyte.
4.1.4 Optimization of GM-CSF and IL-4 Concentrations
Based on the finding that no substrate feeding is necessary for the generation of matured
dendritic cells at a cell density of 1.3 · 106 1mL inoculated monocytes, the influence of different
concentrations of GM-CSF and IL-4 on yield and phenotype of the cells was investigated in
order to get a homogenous DC population.
The next step was to investigate the consumption of GM-CSF and IL-4. Therefore 200,
400 and 800 UmL GM-CSF were inoculated, while IL-4 remained at 500
U
mL . The 200
U
mL were
exhausted completely while in the other two experiments about 300 UmL were consumed (296
U
mL
and 320 UmL respectively), which is shown in figure 4.10 on page 62. The yield and phenotype
was comparable to previous experiments (see figure 4.7, 1.3·106 1mL inoculated monocytes). The
200 UmL GM-CSF concentration resulted in the same number of DCs but in a lower expression
of CD80, CD83 and CD86 (data not shown).
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Table 4.4: The parameters of the optimization of the GM-CSF and IL-4 concentration
Cell densitiy 1.3 · 106 1mL
Donors three
Cultivation system 48 well plates, 500µL volume
Medium X-VIVO 15
GM-CSF 200, 400, 800 UmL
IL-4 500, 1000, 2000 UmL
Maturation stimulus TNF-α (1000 UmL), IL-1β (1000
U
mL),
IL-6 (1000 UmL), PGE2 (1
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
Figure 4.10: GM-CSF consumption of cultivated cells after 8 days. Data shown are the mean
± SD of triplicate cultures from one representative experiment of three performed. From
(Bohnenkamp and Noll, 2003)
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Figure 4.11: Phenotype of DCs generated with different IL-4 concentrations (500 UmL , 1000
U
mL
and 2000 UmL). Only DCs generated with 2000
U
mL resulted in a homogenous population of fully
matured dendritic cells. The data shown are from one representative experiment of 3 performed.
From (Bohnenkamp and Noll, 2003)
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Afterwards the determination of the required IL-4 concentration, which results in a homoge-
nous populations of matured dendritic cells, was performed. Different IL-4 concentrations (500,
1000 and 2000 UmL respectively) with a constant concentration of 800
U
mL GM-CSF, to alter only
one parameter, were inoculated. The IL-4 ELISA indicated that only at an initial concentration
of 2000 UmL the IL-4 was not limiting, as still 25
U
mL were measured after 8 days of cultivation
(data not shown) and phenotypical analysis showed a homogenous population of matured DCs
only for the highest IL-4 concentration (see figure 4.11 on page 63). However, the number of
DCs was similar for all cytokine concentrations.
These results clearly demonstrated that 400 UmL GM-CSF and 2000
U
mL IL-4 are required but
also sufficient for the generation of matured dendritic cells without feeding.
4.1.5 The Influence of Different Maturation Stimuli
In previous experiments for the maturation of dendritic cells a cocktail consisting of TNF-α
(1000 UmL), IL-1β (1000
U
mL), IL-6 (1000
U
mL) and PGE2 (1
µg
mL) was used. In the following ex-
periments the feasibility to simplify this maturation cocktail while obtaining the same yield,
viability, phenotype and distinct functional capacity of DCs were examined. 400 UmL GM-CSF
and 2000 UmL IL-4 were inoculated to differentiate monocytes to dendritic cells. The parameters
of this experiment are listed in table 4.5.
Table 4.5: Experimental parameters to test different maturation stimuli
Cell densitiy 1.3 · 106 1mL
Donors four
Cultivation system 48 well plates, 500µL volume
Medium X-VIVO 15
GM-CSF 400 UmL
IL-4 2000 UmL
Maturation stimulus I TNF-α (1000 UmL), IL-1β (1000
U
mL),
IL-6 (1000 UmL), PGE2 (1
µg
mL)
Maturation stimulus II TNF-α (1000 UmL), PGE2 (18
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
Therefore two maturation cocktails were compared: Cocktail I composed of TNF-α
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(1000 UmL), IL-1β (1000
U
mL), IL-6 (1000
U
mL) and PGE2 (1
µg
mL) (Jonuleit et al., 1997) and
Cocktail II consisted of TNF-α (1000 UmL) and PGE2 (18
µg
mL) (Kalinsky et al., 1998). Using
monocytes from 4 different donors, similar results in yield, viability and phenotype for both
cocktails were obtained (data not shown).
A consequence of maturation can be the secretion of cytokines by dendritic cells (Sallusto
and Lanzavecchia, 1999). In particular, the cytokine IL-12p70 is of major interest because it
polarizes the T-helper cell pathway to a Th1 response (see also figure 2.10 on page 16) However,
it has been demonstrated that PGE2 induces the final maturation of IL-12p70 deficient dendritic
cells (Kalinski et al., 1998). To investigate the amount of bioreactive IL-12p70, the cell
culture supernatant of DCs after 2 days of stimulation with the respective cytokine cocktail
was analyzed by ELISA . With both stimuli no detectable level of IL-12p70 was produced at
any time point (data not shown).
4.1.6 Mixed Leukocyte Reaction
In section 4.1.5 it has been described that dendritic cells matured with either stimulus I or
stimulus II were obtained with the same yield, viability and phenotype. An important readout
of the dendritic cell functionality is the allostimulatory capacity in a mixed leukocyte reaction
(MLR). Thereby, the capacity of dendritic cells of activation of T lymphocytes is determined
by measurement of proliferation (see also Background - MLR on page 67).
The allostimulatory capacity of matured DCs was tested using a ratio of dendritic cells to
T cells of 1:10. After an induction phase cells were fed twice at 92h and 163h by replacement of
50% of the medium and adding of 100 UmL IL-2. Figure 4.12 on page 66 illustrates the potent stim-
ulatory capacity of dendritic cells matured with either cytokine stimulus I: TNF-α (1000 UmL),
IL-1β (1000 UmL), IL-6 (1000
U
mL) and PGE2 (1
µg
mL) or stimulus II: TNF-α (1000
U
mL) and PGE2
(18 µgmL). In contrast, immature dendritic cells failed to induce a potent allostimulatory response
of T lymphocytes.
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Figure 4.12: Allostimulatory capacity for PBMC from healthy donors. DCs matured with dif-
ferent maturation stimuli (stimulus I: TNF-α (1000 UmL), IL-1β (1000
U
mL), IL-6 (1000
U
mL) and
PGE2 (1
µg
mL); stimulus II: TNF-α (1000
U
mL) and PGE2 (18
µg
mL)) induced a similar stimulatory
capacity in the allogeneic MLR. Shown are mean values ± SD from three different experiments
in triplicates. From (Bohnenkamp and Noll, 2003)
Figure 4.13: Phenotype of PBMC after MLR. Either maturation stimulus I and II induced
IFN-γ producing T cells which were also CD25 (IL-2 α-chain) positive. Results are expressed
as mean ± SD from three experiments in triplicates. From (Bohnenkamp and Noll, 2003)
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Background - MLR: The mixed leukocyte reaction is a test for the stimulatory
capacity that is induced by dendritic cells. In the presence of allogeneic (two indi-
viduals or cell populations that differ in their MHC complexes) T cells, dendritic
cells induce a strong activation based on the different MHC types. The more MHC
complexes and co-stimulatory molecules dendritic cells express the better T cells are
stimulated. T cell activation is determined by their proliferation, e.g. DNA synthe-
sis (BrdU incorporation), expression of ’proliferation markers’ like CD25, the high
affinity IL-2 receptor, and CD71, the transferrin receptor, or counting of proliferat-
ing cells. Usually, dendritic cells and T cells are co-cultivated at different ratios, to
analyze up to which dilution T cells are stimulated (Nguyen et al., 2003).
There are two modes of cross-reactive recognition that may explain the alloreactivity
of T cells. Allogeneic T cells can be activated in a peptide-dominant way, recognizing
the peptide expressed by the non-self MHC complexes. On the other hand, the
allogeneic MHC molecule may fit to the T cell receptor and may give a tight binding
that is less dependent on the peptide bound to the MHC molecule (Janeway et
al., 2001).
Testing of the supernatant of the MLR after 4 days for levels of IL-12p70 showed no de-
tectable amount of cytokine. Since PGE2 suppressed IL-12p70 production in matured DCs, it
was investigated whether a typical Th1 or Th2 cytokine pattern was being induced. After 190h
of cultivation and proliferation of T lymphocytes, cells were tested for IFN-γ by a cytokine
secretion assay. Either T cells stimulated by DCs matured with cocktail I or II were IFN-γ
and CD25 positive (see figure 4.13 on page 66). Performed ELISA for IL-4 showed no level of
cytokine (data not shown). These data suggest that T lymphocytes stimulated by DCs matured
by either cytokine stimulus were polarized towards the Th1 type dendritic cell.
4.1.7 Generation of Dendritic Cells with Optimized Parameters
Based on the optimized parameters, the generation of dendritic cells was carried out in 75cm2
tissue culture flasks with a volume of 30mL. Monocytes were inoculated at a cell density of
1.3 · 106 1mL and differentiated with 400 UmL GM-CSF and 2000 UmL IL-4 (see table 4.7). On day 6
1000 UmL TNF-α and 18
µg
mL PGE2 were added for additional 2 days for maturation of DCs. On
day 8 the cells were harvested (see also table 4.7 on page 70).
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Table 4.6: The results of the generation of dendritic cells using the optimized protocol
(n = 8) Mean Standard deviation
Inoculated cells [ 1mL ] 10.9 · 105 1.0 · 105
Number of immature DCs on day 6 [ 1mL ] 7.0 · 105 2.4 · 105
Yield of immature DCs [%] 64.2 22.3
Number of matured DCs on day 8 [ 1mL ] 7.2 · 105 1.5 · 105
Yield of matured DCs [%] 66.3 13.6
Purity (FSC / SSC) [%] 95.4 2.1
Viability (Trypan blue dye exclusion) [%] 93.4 5.9
Number of matured DCs per buffy coat [-] 5.8 · 107 1.2 · 107
Figure 4.14: Phenotypical analysis of mature DCs generated with the standardized protocol.
Shown are results of surface antigen expression as indicated as mean ± SD from 8 independent
experiments. From (Bohnenkamp and Noll, 2003)
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Figure 4.15: Expression of surface antigens on matured DCs from one typical donor out of 8.
Outlined histograms represent isotype staining. Histograms indicate gated cells.
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Table 4.7: Optimized parameters for the generation of dendritic cells
Cell densitiy 1.3 · 106 1mL
Cultivation system 75cm2 tissue culture flasks, 30mL volume
Medium X-VIVO 15
GM-CSF 400 UmL
IL-4 2000 UmL
Maturation stimulus TNF-α (1000 UmL), PGE2 (18
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
During the differentiation of monocytes to fully mature dendritic cells from 8 different donors
no difference was observed regardless of the cultivation system (48 well plates compared with
tissue culture flasks). The mean yield as calculated from inoculated CD14+ monocytes was
66.3± 13.6% with a mean viability of 93.4± 5.9% (n = 8), which is shown in table 4.6 on page
68. Figure 4.14 illustrates the mean percentage of positive dendritic cells for important surface
antigens like HLA-DR, HLA-A,B,C, co-stimulatory molecules like CD40, CD80 and CD86, the
intercellular adhesion molecule ICAM-1 and the maturation marker CD83 of dendritic cells.
The expression of surface proteins from one representative donor is demonstrated in figure 4.15
on page 69.
4.2 Apoptosis of Monocytes
The optimized protocol for the standardized generation of monocyte-derived dendritic cells
resulted in a yield of 66.3±13.6% with a mean viability of 93.4±5.9% (n = 8). In this context,
an important question is whether the yield of DCs is determined by the cultivation method or
by the properties of the monocytes being used.
The aim of the following experiments was to investigate whether the degree of apoptosis
of the starting population of CD14+ enriched monocytes is the crucial parameter determining
the yield of matured monocyte-derived dendritic cells. As programmed cell death regulates the
monocytes population in vivo, the analysis of CD14+ enriched monocytes by flow cytometry
for apoptosis using an assay for phospatidylserine expression on early apoptotic cells with
fluorescein labeled annexin V combined with propidiumiodide staining, originally developed by
Vermes et al. (1995), was carried out.
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Background - apoptosis of monocytes: Monocytes play a major role as cir-
culating precursors of the different types of macrophages and dendritic cells and
participate in inflammatory responses by releasing cell-signaling molecules (Fahy
et al., 1999, Lund et al., 2001). The number of monocytes, which migrate into
tissue, generally exceeds the number needed to replace dying macrophages or den-
dritic cells. Excess monocytes, entering non-inflamed tissue, are therefore removed by
resident macrophages (Mangan et al., 1991). On the other hand, up-regulation
of the number of monocytes during inflammatory responses may be required. In
general, the balance of cell proliferation and removal is crucial for the regulation of
cell populations (Kerr et al., 1972). Additionally, as a part of normal physio-
logical cell processes, apoptosis regulates equilibrium between cell proliferation and
cell death (Vermes et al., 2000). In considering the differentiation of monocytes from
freshly isolated peripheral blood, it is likely that some of the monocytes are apop-
totic and cannot be differentiated to DCs. Moreover, the culture environment and
the isolation procedure itself (Lund et al., 2002) may affect the level of apop-
tosis. Thus, when cultured in medium in the absence of an appropriate stimulus,
monocytes rapidly undergo programmed cell death (Mangan et al., 1991).
Background - annexin V: The phenomenon of highly asymmetric biological
membranes is not only restricted to membrane proteins but also found in the dis-
tribution of lipids (Bevers et al., 1989). An extreme distribution is found for
phospatidylserine (PS), which is almost entirely located in the inner side of the
plasma membrane. An alteration of plasma membrane asymmetry occurs early af-
ter the onset of the execution phase of apoptosis and results in the translocation
of PS from the inner to the outer layer of the plasma membrane (Cornelissen
et al., 2002). When PS is initially exposed on the outer surface, the membrane
integrity has not been compromised and no nuclear disintegration and alterations
in the cytoplasm are detectable (van Engeland et al., 1998). By combining the
annexin V staining, which was shown to have a high affinity for PS, with propidiu-
miodide (PI), discrimination between early apoptotic cells (annexin V +, PI−) and
late apoptotic or necrotic cells (annexin V +, PI+) is possible.
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Table 4.8: Analysis for annexin V (AV) and propidiumiodide (PI) of monocytes after CD14
enrichment by immunomagnetic bead selection. From (Bohnenkamp et al., submitted)
Yield of monocytes AV+PI− AV+PI+
after enrichment Apoptotic cells Necrotic cells
[%] of PBMCs [%] of monocytes [%] of monocytes
Donor 1 6.9 29.9 0.8
Donor 2 8.6 37.7 0.2
Donor 3 17.9 62.6 1.2
Donor 4 10.0 34.5 1.6
Donor 5 18.7 23.7 0.3
Donor 6 13.5 33.2 0.3
Donor 7 14.7 45.9 0.2
Donor 8 12.2 34.5 0.1
Mean 12.8 37.8 0.6
Standard deviation 4.0 11.1 0.5
Monocyte apoptosis and the fate during differentiation to matured dendritic cells
As the yield from monocyte-derived dendritic cells was 66.3±13.6%, the initial studies focused
on analysis of monocyte apoptosis and viability. After enrichment of monocytes by immunomag-
netic beads (see also chapter 4.1.1), the CD14+ cell population showed evidence of apoptosis
determined by annexin V staining. As shown in table 4.8, the mean of 8 different donors was
37.8%, varying between 23.7% and 62.6%.
After this finding it was aimed to follow the fate of apoptotic monocytes during differentia-
tion to matured dendritic cells. 10.9 ·105±1.0 ·105 1mL CD14+ monocytes (n = 8) in X-VIVO 15
containing GM-CSF and IL-4 were inoculated into tissue culture flasks and the non-adherent
population was analyzed by flow-cytometry for apoptosis and by staining for viable cells. Figure
4.16 on page 73 shows the flowcytometrical analysis from one donor and Figure 4.17 illustrates
the changes in the viable cells and apoptotic cells in the non-adherent population over time. The
viable cell number decreased rapidly on day 1 when viable monocytes attached to the surface of
the tissue culture flask while most apoptotic cells remained non-attached (this represents 53%
of initial apoptotic cell number for the case illustrated in Figure 4.17).
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Figure 4.16: Analysis of one representative donor out of 8 for annexin V and propidiumio-
dide during differentiation of monocytes to dendritic cells. Only suspension cells were stained,
attached cells were not analysed. From (Bohnenkamp et al., submitted)
Figure 4.17: Number of cells in suspension for one representative donor out of 8. Results are
from triplicates and expressed as mean ± standard deviation. From (Bohnenkamp et al.,
submitted)
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Figure 4.18: Yield of immature and TNF-α and PGE2 matured dendritic cells. Results are from
8 different donors and presented as mean ± standard deviation. Shown are viable (AV− / PI−)
and apoptotic (AV+ / PI−) cells. From (Bohnenkamp et al., submitted)
After 6 days of differentiation most of the apoptotic cells have disappeared and the cells
found in suspension represent immature dendritic cells (increased to 7.2± 0.4 · 105 1mL for one
representative donor) as determined by the expression of high levels of HLA-A,B,C and HLA-
DR, weak levels of CD1a, CD80, CD83 and CD86 and no expression of CD14 (data not shown).
An analysis of the number of annexin V positive cells present after differentiation for 6 days
showed that this value decreased on average to just 1.0 ± 0.9% (Figure 4.18). The addition
of TNF-α and PGE2 induced maturation of the DCs, as demonstrated by the high expression
of HLA-A,B,C, HLA-DR, CD80, CD83 and CD86, a weak level of CD1a and no expression
of CD14 (see figure 4.15 on page 69). However, the percentage of apoptosis was increased to
8.8 ± 9.3% (n = 8) of all suspension cells on day 8 (illustrated in figure 4.18). Thus, in the
presence of the maturation cytokines, the number of viable cells decreased slightly, while an
increased number of apoptotic cells was observed.
These results suggest that GM-CSF and IL-4 prevent monocytes from undergoing further
spontaneous apoptosis. Moreover, phospatidylserine presenting monocytes were apparently re-
moved by phagocytosis by viable monocytes or immature dendritic cells resulting in a homoge-
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nous, viable cell population on day 6. Using the protocol described, the yield of dendritic cells
was calculated considering only viable, non-apoptotic monocytes and DCs. Combining the data
from the 8 donors, the yield (as defined by size of cells, morphology, surface antigen expression
and apoptosis) of immature DCs and of matured DCs was 91.2±26.8% and 90.2±16.6 (n = 8)
respectively (figure 4.18).
4.3 Induction of MUC1 Specific T Lymphocytes
In the chapters 4.1 and 4.2 the development of a reproducible and standardized protocol for
the generation of monocyte-derived dendritic cells was described. With GM-CSF and IL-4 DCs
differentiate in the medium X-VIVO 15 under serum-free conditions in 6 days to immature
dendritic cells. Additionally, it was shown that the cytokine cocktail TNF-α and PGE2 induced
maturation, which resulted in a homogenous population of fully matured dendritic cells. Fur-
thermore, the percentage of apoptotic monocytes in the starting population was proved to be
crucial for the determination of the yield of dendritic cells.
In the following chapter different in vitro assays were established to investigate the function-
ality of DCs. Above all, a dendritic cell system based on lysate-pulsed DCs was to be developed
that efficiently present tumor-associated antigens for induction of a strong T cell response.
The following questions regarding the immunobiological functionality of dendritic cells were
addressed:
• A reproducible method for lysate preparation
• Antigen uptake of DCs
• Lysate-pulsing and maturation
• Migration towards important chemokines
• Cryopreservation of dendritic cells
• MHC class I restricted T cell responses
• Induction of autologous T cells with lysate-pulsed DCs
The goal of the described experiments was to investigate whether lysate-pulsed dendritic
cells induce tumor-associated antigen specific T lymphocytes in an MHC class I restricted
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Figure 4.19: Analysis of MUC1 expression on the breast carcinoma cell lines MCF-7 and
MDA-MB-231 with the antibodies 12c10, which binds outside the tandem repeat, HMFG-1
(binds to a epitope defined as PDTR) and SM-3 (binds to a epitope defined as PDTRP). From
(Bohnenkamp et al., in preparation)
fashion. MUC1, which is expressed by the breast carcinoma cell lines MCF-7 and MDA-MB-
231, was used as a model antigen. For detection of MUC1 specific T cells, tetramers with the
M1.2 (Brossart et al., 1999) and F7 (Heukamp et al., 2001) peptides, both localized
within the signal sequence of MUC1, were chosen. Furthermore, the induction of a strong Th1
polarized response by lysate-pulsed DCs matured with the adjuvants TNF-α and PGE2 were
investigated. Because the dose as well as the type and structure of the antigen influences the
differentiation and polarization of an induced immune response, the cytokine profile induced
by lysate-pulsed DCs and the secreted cytokines induced by DCs pulsed with the MHC class I
restricted peptides FLU M1 and Melan-A / Mart-1 was analyzed.
4.3.1 Evaluation of Breast Carcinoma Cell Lysates
The delivery of tumor-associated antigens to dendritic cells is critical for the induction of a
strong T cell response. Consequently, the preparation method for lysates from cancer cells need
to be a simple procedure under sterile conditions and result in the solubilization of unaltered
proteins. Lysates from breast carcinoma cell lines were evaluated utilizing MUC1 as model
tumor-associated antigen, on which the experiments were based.
The expression of MUC1 on the breast carcinoma cell lines MCF-7 and MDA-MB-231 was
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Figure 4.20: Detection of MUC1 with HMFG-2 (binds to an epitope defined as DTR) antibody.
Western blot analysis of MCF-7 lysate from three independent experiments. Lysate was pre-
pared by four repetitive freeze and thaw cycles (thawing at 4◦C by sonication). As a control a
standard lysate buffer was used. From (Bohnenkamp et al., in preparation)
determined by flow cytometry using the 12c10 monoclonal antibody, which binds to epitopes
outside the tandem repeat region, and the HMFG-1 and SM-3 monoclonal antibodies, which
react with a core protein epitope defined as PDTR and PDTRP respectively (figure 4.19)
(Blockzjil et al., 1998). The difference in MUC1 expression by both cell lines was evident.
The MCF-7 cell line showed higher expression compared with the MDA-MB-231 cell line as
determined by 12c10 and HMFG-1 antibody (also reported by Walsh et al. (2000)). How-
ever, MDA-MB-231 proved to show a more homogeneous expression level of MUC1 (the relative
variation from cell to cell).
Usually, for the generation of lysate-pulsed dendritic cells, the lysates are prepared by repet-
itive freez-thaw cycles. However, the method of choice need to avoid proteolytic reactions by
active proteases or phosphatases and need to solubilize all cell proteins without degradation.
For this reason, lysates were prepared at low temperatures (≤ 4◦C) and lysis of tumor cells was
performed by four freeze-thaw cycles: thawing was done by sonication at 4◦C in an ultrasonic
bath. Lysates from carcinoma cell lines were tested for MUC1 by western blot analysis and
compared with a homogenate prepared with standard lysis buffer. As demonstrated in figure
4.20, freeze-thaw lysates contained MUC1 protein at nearly the same concentration as stan-
dard lysates. Furthermore, it was shown in three independent experiments that the preparation
method was highly reproducible.
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4.3.2 Immature DCs Efficiently Take Up Antigen
Because of antigens have to be taken up efficiently by dendritic cells, the endocytosis of model
antigens by DCs prepared using the method described in chapter 4.1 on page 49 was analyzed.
So, model antigens labeled with a fluorescent dye are loaded on immature DCs, incubated for a
certain time and analyzed by a flowcytometer. As antigens labeled dextran, lipopolysaccharide
and collagen-I labeled microspheres with a size of 2µm were used. In table 4.9 the parameters
such as incubation time and concentration of the corresponding antigen are listed.
Table 4.9: Parameters for the evaluation of the antigen uptake by dendritic cells
Dextran LPS Microspheres
Concentration 1mgmL 20
µg
mL 1.0 · 106 1mL
Incubation time 2h 2h 2h and 20h
Number of DCs 1.0 · 105 1mL 1.0 · 105 1mL 1.0 · 105 1mL
Day of differentiation d6 d6 d6 / d8
Monocyte-derived dendritic cells were generated with the described protocol. After 6 days
of differentiation in the presence of GM-CSF and IL-4 immature dendritic cells were incubated
with the antigens FITC conjugated dextran and Alexa-Fluor-488 conjugated LPS, as well as
collagen-I labeled microspheres (size of 2µm) at 37◦C. As negative control cells were incubated
with the same antigen and concentration at 0◦C. The uptake of the different compounds is
shown in figure 4.21. Immature dendritic cells took up dextran and LPS compared with the
negative control.
The histograms that plots the uptake of the incubated microspheres demonstrates the ef-
ficient macropinocytosis of incubated collagen-I labeled beads. In these histograms every peak
corresponds to the number of endocytozed microspheres: The higher the fluorescence intensity
the more beads are taken up. Furthermore, a prolonged incubation time increased the number
of pinocytozed beads. Mature dendritic cell showed a reduced endocytic capacity compared
with immature DCs.
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Figure 4.21: Analysis of the capacity of immature (d6) and matured (d8) DCs to endocy-
tose different antigens. FITC labeled dextran (1mgmL), Alexa-Fluor-488 labeled LPS (20
µg
mL) and
collagen-I microspheres (1.0 · 106 1mL) were compared. Shown is one representative experiment
out of four. From (Bohnenkamp et al., in preparation)
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4.3.3 Adjuvant Induced Maturation of Lysate-pulsed Dendritic
Cells
In section 4.3.2 it has been confirmed that immature dendritic cells efficiently take up antigens,
which were loaded in a solubilized form on the cells. Thereby, different concentrations varying
between 20 µgmL (LPS) and 1
mg
mL (dextran) were used. In this section the influence of different
breast carcinoma cell lysates and lysate concentrations was investigated. Moreover, the contri-
bution of the lysate to the maturation of DCs and the necessity for adaption of the maturation
cytokine cocktail consisting of TNF-α and PGE2 was investigated.
To investigate the effect of tumor cell lysates on dendritic cells, lysates containing total
protein levels of 50 µgmL up to 300
µg
mL of both cell lines were incubated with DCs on day 6 for
48h. Lysate concentrations of 150 µgmL and higher were found to decrease the yield and viability
of harvested DCs (data not shown). None of the concentrations of protein induced maturation
as determined by the expression of low levels of HLA-A,B,C, weak levels of CD80, CD83 and
CD86 (data not shown). As indicated by these results, protein lysates from MCF-7 and MDA-
MB-231 breast carcinoma cell lines were not immunogenic and therefore did not mature loaded
dendritic cells making the addition of a maturation stimulus necessary.
To induce maturation 100 µgmL protein (equivalent to approximately one tumor cell per DC)
were used, the highest concentration which did not decrease yield and viability, and additionally,
as adjuvants, TNF-α (1000 UmL) and PGE2 (1
µg
mL). Surface receptor analysis demonstrated that
DCs pulsed with 100 µgmL lysate (MCF-7 or MDA-MB-231) and matured with TNF-α (1000
U
mL)
and PGE2 (1
µg
mL) were comparable to DCs matured with TNF-α (1000
U
mL) and PGE2 (18
µg
mL)
(figure 4.22). Both maturation stimuli resulted in high levels of MHC class I and MHC class II
molecules, the costimulatory proteins CD80 and CD86 and the maturation marker CD83.
Assessment of the allostimulatory capacity in a mixed leukocyte reaction comparing MCF-7
and MDA-MB-231 lysate-pulsed DCs showed slight differences in T cell activation analyzed by
CD25 (α-chain of the IL-2 receptor) and CD71 (transferrin receptor), which is illustrated in
the figures 4.23 and 4.24 on page 82. Analysis of IL-12p70, IFN-γ, TNF-α, IL-2, IL-4, IL-5 and
IL-10 in the supernatant of lysate-pulsed matured DCs evidenced a DC phenotype, which did
not secrete any of the determined cytokines (data not shown).
As described in chapter 4.2, monocytes from PBMCs contain a high percentage of apoptotic
cells (37.8% ± 11.1%, as shown in table 4.8 on page 72), which need to be considered in the
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Figure 4.22: After a 48 h incubation with TNF-α and PGE2 or with lysate in the presence of
TNF-α and PGE2 DCs highly express the surface molecules MHC class I (HLA-A,B,C) and
MHC class II (HLA-DR), CD80, CD86 and the maturation marker CD83. Outlined histograms
represent isotype staining. Histograms correspond to gated cells. From (Bohnenkamp et al.,
in preparation)
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Figure 4.23: Activation of positive T cells (CD3) was assessed by CD25 (α-chain of the IL-2 re-
ceptor) staining after 4 days of co-cultivation. Results are from three different donors (triplicate)
and are presented as mean ± SD. From (Bohnenkamp et al., in preparation)
Figure 4.24: Activation of positive T cells (CD3) was assessed by CD71 (transferrin receptor)
staining after 4 days of co-cultivation. Results are from three different donors (triplicate) and
are presented as mean ± SD. From (Bohnenkamp et al., in preparation)
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Figure 4.25: Yield of matured DCs pulsed with 100 µgmL lysate of breast carcinoma cell lines
MCF-7 and MDA-MB-231 in the presence of TNF-α and PGE2. Results are from 6 (MCF-7)
and 3 (MDA-MB-231) different donors and presented as mean ± SD. Viable (AV− / PI−) and
apoptotic (AV+ / PI−) cells are shown. From (Bohnenkamp et al., in preparation)
determination of the yield. By using an annexin V propidiumiodide assay, only viable, non-
apoptotic monocytes and DCs were applied to calculation. The yield of MDA-MB-231 and
MCF-7 lysate-pulsed, matured dendritic cells (as defined by size of cells, morphology, surface
antigen expression and apoptosis) was 75.6±3.1% (n = 3) and 91.8±18.8% (n = 6) respectively,
which is illustrated in figure 4.25. Furthermore, the percentage of apoptotic DCs was 12.3±6.0%
and 8.2± 11.4% respectively.
4.3.4 Migratory Capacity of Lysate-pulsed Dendritic Cells
Dendritic cell migration is essential for the initiation of an adaptive immune response. After
maturation, the chemokine receptor CCR7 is up-regulated on dendritic cells. Thus, activated
DCs home to lymphoid organs, where the CXCR4 and CCR7 ligands CXCL12 and CCL19
are expressed and the T cell stimulation takes place. In conclusion, the homing of DCs from
peripheral tissues to the draining lymph nodes is crucial for the stimulation of T cells. Therefore,
the migratory capacity of lysate-pulsed matured DCs was analyzed by surface protein expression
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of CXCR4 and CCR7 and a chemotaxis assay towards the chemokines CXCL12 (SDF-1α) and
CCL19 (MIP-3β).
The chemotaxis towards the chemokines CXCL12 (250 ngmL) and CCL19 (100
ng
mL) was in-
vestigated using a transwell assay (6µm pore size). As negative control a chamber without
chemokines was used. 1 · 105 cells were incubated at 37◦C and counted after 2h of incubation.
As demonstrated in figure 4.27 on page 85, matured DCs expressed both the receptors
CXCR4 and CCR7. MCF-7 and MDA-MB-231 lysate-pulsed DCs showed efficient migration
towards the indicated chemokines (figure 4.26 on page 85). However, MCF-7 lysate-pulsed DCs
demonstrated an about 20% lower migratory capacity towards CCL19 (MIP-3β).
Scanning electron microscopy (SEM) image analysis demonstrated the effective migration
of matured dendritic cells towards chemokines. Figure 4.28 and 4.29 on page 86 show the top
of the membrane after 2h of incubation with the chemokine CCL19. Cells were assembling
around the pores of the membrane towards highest chemokine concentration and demonstrated
a stretched shape. Figure 4.30 illustrates a part of a dendritic cell in a pore of the membrane.
4.3.5 Cryopreservation of Dendritic Cells
The development of a protocol for the cryopreservation of dendritic cells is a key step not only
to facilitate the use of DCs for in vitro assays (for the restimulation of T cells), but also to
assist vaccination strategies, in which DCs are repetitively re-infused into the patient. However,
it is commonly accepted that PBMCs can be easily frozen by using fetal calf serum (FCS) with
10% dimethyl sulfoxide (DMSO). In this experiment the development of an optimized protocol
for the cryopreservation of dendritic cells was carried out, to avoid the usage of non-autologous
components, which are not in accordance to GMP requirements.
For cryopreservation, lysate-pulsed dendritic cells matured with the adjuvants TNF-α and
PGE2 were frozen in autologous plasma (fluid phase of blood that is not coagulated), which
had been heat-inactivated, centrifuged and filtered before usage, with 10% DMSO. Notably, the
freezing of immature DCs was also a possible option. Nevertheless, readily matured and antigen
loaded DCs facilitate the handling and were therefore preferred to immature DCs. Dendritic
cells were frozen at cell densities varying between 1.1 ·106 and 3.5 ·106 1mL and thawed after one
week. The mean yield was 85.3 ± 9.4% and the viability 89.3 ± 6.0%, which is shown in table
4.10 on page 88. The flowcytometrical analysis demonstrated no difference of surface protein
expression between frozen and freshly prepared dendritic cells (data not shown).
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Figure 4.26: Migration of lysate-pulsed DCs towards the chemokines CCL19 (MIP-3β), CXCL12
(SDF-1α) or without chemokines (NEG). Data represent the means ± standard deviation of
experiments from 3 different donors. From (Bohnenkamp et al., in preparation)
Figure 4.27: Analysis of CXCR4 and CCR7 expression on MCF-7 or MDA-MB-231 lysate-pulsed
DCs in the presence of TNF-α and PGE2. Data are representative of 3 separate experiments.
From (Bohnenkamp et al., in preparation)
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Figure 4.28: Electron microscopy image (magnification: 1,024x) of the top of the membrane
after the chemotaxis assay. Dendritic cells migrated towards CCL19.
Figure 4.29: Electron microscopy image (magnification: 10,080x) of the top of the membrane
after the chemotaxis assay towards CCL19.
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Figure 4.30: SEM image after the chemotaxis assay. Shown is a high magnification (16,490x)
picture of a dendritic cell in a pore of the membrane.
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Table 4.10: Cryopreservation of lysate-pulsed dendritic cells generated from 6 different donors
Frozen DCs [-] Thawed DCs [-] Yield [%] Viability [%]
Donor1 1.1 · 106 9.0 · 105 82.1 87.2
1.1 · 106 1.1 · 106 95.6 88.3
Donor 2 1.3 · 106 1.2 · 106 92.3 79.4
1.3 · 106 1.1 · 106 82.8 89.5
Donor 3 3.0 · 106 2.3 · 106 76.6 83.3
3.0 · 106 3.0 · 106 98.8 83.1
Donor 4 3.3 · 106 3.3 · 106 98.7 87.6
3.3 · 106 2.5 · 106 75.2 86.0
Donor 5 1.7 · 106 1.6 · 106 92.3 94.0
1.7 · 106 1.2 · 106 71.8 98.0
Donor 6 3.5 · 106 2.7 · 106 75.7 98.0
3.5 · 106 2.9 · 106 81.7 97.1
Mean 85.3 89.3
Standard deviation 9.4 6.0
4.3.6 Matured DCs Induce MHC Class I Restricted T Cell Re-
sponses
The goal of the following experiments was to demonstrate the functionality of the generated
dendritic cells to launch an MHC class I restricted T cell response. Furthermore, this stimulation
protocol was also developed to setup and optimize the stimulation of T cells with lysate-
pulsed dendritic cells (section 4.3.7). The parameters used for these experiments are listed
in table 4.11 on page 93. Additionally, the results of this section will be compared with the
autologous stimulation with lysate-pulsed DCs for qualitative and quantitative estimation of
the functionality and effects of the generated DCs on T cells.
To investigate an MHC class I restricted T cell response, the immunodominant HLA-A*0201-
restricted peptide FLU M1 of the human influenza virus matrix protein (Gotch et al.,
1987; Pogue et al., 1995) and the Melan-A / Mart-126−35 analogue ELAGIGILTV A27L
(Kawakami et al., 1994; Romero et al., 1997; Valmori et al., 1998) were used.
These antigens were chosen because FLU M1 elicits a classical memory T cell response and the
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frequency of Melan-A / Mart-1 specific T cells in the blood of HLA-A2 individuals was reported
to be considerably higher (10−3) compared to the mean CTL frequency of approximately 10−6
(Coulie et al., 2003). Furthermore, it was shown that most of the anti-Melan-A / Mart-1-
A2 lymphocytes present in the blood of individuals without melanoma have a naive phenotype
(Zippelius et al., 2002). In sum, it was aimed to induce a memory T cell response by
stimulating with FLU M1 peptide-pulsed DCs and a naive T cell response by priming with
Melan-A / Mart-1 peptide-pulsed DCs.
Dendritic cells were loaded with the appropriate peptide, β2-microglobulin and the helper
peptide PADRE (Alexander et al., 1994, Brossart et al., 1999), which is shown in
figure 4.32 on page 92. Thereby, the correct conformation of MHC class I molecules, which are
loaded with peptides, is induced by β2-microglobulin (see also Background - Tetramer
analysis). Additionally, the PADRE helper peptide binds to MHC class II molecules and
activates CD4+ helper T cells resulting in cytokine production and further support for primed
cytotoxic T cells. T lymphocytes were co-cultivated with DCs at a ratio of 10:1 in the presence
of 2400 UmL IL-7 for preventing apoptosis of T cells. After 7 days most of the CD4
+ T cells were
depleted with CD4 mAb coated tissue culture dishes and remaining cells were co-stimulated
with DCs (without PADRE) at a ratio of 20:1 in fresh medium containing 20 UmL IL-2, the T
cell growth factor. The culture was fed every 2nd day according to the proliferation of T cells.
In figure 4.33 on page 93 the proliferation of FLU M1 and Melan-A / Mart-1 stimulated T
cells is illustrated. As negative control TNF-α and PGE2 matured, but unpulsed dendritic cells
were used. The high expansion of FLU M1 T cells was evident, whereby Melan-A / Mart-1
induced T cells proliferated slower (see table 4.12). Matured, but unpulsed DCs did not induce
proliferation in this autologous stimulation.
Already, after two stimulations 19.7% of T cells were shown to be FLU M1 peptide specific
as determined by tetramer staining (figures 4.34 and 4.35 on page 94) and 45.9% were specific
to Melan-A / Mart-1 peptide (figures 4.36 and 4.37 on page 95). Due to a stronger proliferation
of FLU M1 stimulated T cells, the expansion factors were determined to 276-fold (Melan-A /
Mart-1) and 4369-fold (FLU M1) respectively.
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Background - analyzing T lymphocytes: Typically, inactive T cells are small
featureless cells with few cytoplasmic organelles and much of the nuclear chromatin
inactive (Janeway et al., 2001). These small lymphocytes have no functional
activity until they recognize antigen for the induction of proliferation and their
differentiation to specialized effector T cells.
In fact, T cells are important mediators of the effector mechanisms after dendritic cell
stimulation and possess distinct immunobiological functions (see also chapter 2.2.3).
The outcome of this is the necessity of functional distinction of immune responses
and the assessment of the quantitative and qualitative nature of a T cell response.
Therefore, different in vitro assays were established to investigate the phenotype,
proliferation and activation of T cells and their specificity by tetramer staining:
T cell subsets: T cells (CD3+) can be subdivided into several populations: T-
helper cells (CD4+) and cytotoxic T cells (CD8+). Additionally, T-helper cells can
be assigned to one of the several subsets including Th1 and Th2 cells (see also figure
2.10 on page 16). Theses cell are classified by the types of cytokines that are secreted:
Th1 cells produce IL-2, IFN-γ and TNF-α, Th2 cells secrete IL-4, IL-5 and IL-10.
Proliferation of T cells: For the evaluation of proliferation of T cells that oc-
curs following stimulation, various methods have been established (see also chapter
4.1.6). However, simple enumeration of T cells is laborious, and in most cases not
possible because cells that respond represent only a small percentage of the total
cell population (Hickling, 1998). For that reason, DNA synthesis (BrdU incor-
poration) or expression of ’proliferation markers’ like CD25, the high affinity IL-2
receptor, and CD71, the transferrin receptor, are useful tools for the evaluation of
proliferation.
Expression of activation markers: The analysis of activation markers on the
cell surface of T cells can be correlated with the proliferation of T cells. Especially,
CD25 and CD71 show a good correlation (Nguyen et al., 2003). Another acti-
vation marker, CD69, is up-regulated during 24h after activation and is therefore a
good indicator for the induction of T cells (Craston et al., 1997; Rutella et
al., 1999). However, proliferation does not correlate with the percentage of CD69+
positive T cells because this surface protein is downregulated after the induction
phase.
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Background - Tetramer analysis: This technique enables the identification of
individual T cells on the basis of their specific binding to the MHC:peptide complex.
Due to the low affinity of one MHC class I molecule to the T cell receptor (TCR)
(fast ’off-rate’), rapid dissociation of the TCR from the MHC:peptide complex can be
observed. Therefore, multimeres (tetramer) of the MHC:peptide complex are built
to overcome these limitations.
The restricting MHC molecule is synthesized in a soluble form by E. coli. These
peptides can be biotinylated using the enzyme BirA, which recognizes a specific
amino acid sequence. At this stage, MHC molecules are not correctly folded. The
correct conformation is induced by the addition of β2-microglobulin and the pep-
tide that represents the appropriate epitope (compare the method for the peptide
loading of DCs - both β2-microglobulin and peptides are loaded on DCs). Next, the
biotinylated and correctly folded MHC:peptide complex is mixed with streptavidin,
which contains four binding sites for biotin and has previously been tagged with
a fluorochrome. This results in the formation of an MHC:peptide tetramer - four
specific MHC:peptide complexes bound to a single molecule streptavidin, which is
labeled by a fluorescent dye (see figure 4.31).
Indeed, the four binding sites of a tetramer result in a greater affinity for T cells
compared with a monomeric MHC class I molecule (Hickling, 1998). With this
method, CD8+ T cell responses can be analyzed accurately. It is quantitative, can
be combined with the phenotypical analysis of T cells and large numbers of samples
can be processed. The lowest frequency that can be detected is one CTL in 50,000
(Hickling, 1998).
MHC class I
peptide
streptavidin fluorescent dye
Figure 4.31: MHC:peptide complexes are formed to tetramers by coupling to streptavidin
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Figure 4.32: The scheme of the autologous stimulation of T cells with peptide-pulsed den-
dritic cells. Before stimulation, matured DCs were loaded with the appropriate peptide, β2-
microglobulin and the helper peptide PADRE and co-cultivated for 7 days. This was followed
by an additional stimulation. Seven days after the 2nd stimulation T cells were analyzed for
their specificity by tetramer staining.
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Table 4.11: The parameters of the experiments for the autologous stimulation of T cells
Cell density 1.0 · 106 1mL
Ratio DCs to T cells 1:10 (1st stimulation), 1:20 (2nd stimulation)
Pulsing of DCs 40 µgmL peptide (1
st stimulation), 20 µgmL peptide (2
nd stimulation)
Volume 12mL
Medium AIM V, serum-free
Donors two
Cultivation system Tissue culture flasks
IL-7 2400 UmL , 1
st day
IL-2 20 UmL , 7
th day
Feeding every 2nd day (medium + 20 UmL IL-2)
Cultivation time 14 days
Figure 4.33: Autologous PBMCs were induced with peptide-pulsed DCs with IL-7 for 7 days
and restimulated for additional 7 days with 20 UmL IL-2. Analysis of specificity was assessed by
tetramers folded around the corresponding peptide. Shown is one representative donor out of
two.
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Figure 4.34: Tetramer analysis of FLU M1 stimulated T cells. Dot plots correspond to gated
cells. From (Bohnenkamp et al., submitted)
Figure 4.35: Number and expansion of FLU M1 specific T cells before and after stimulation.
Inoculated were 1.0 · 106 1mL PBMC in 4mL AIM V medium (triplicate). From (Bohnenkamp
et al., submitted)
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Figure 4.36: Melan-A / Mart-1 specific T cells analysed by corresponding tetramer. Dot plots
indicate gated cells. From (Bohnenkamp et al., submitted)
Figure 4.37: Number and expansion of Melan-A / Mart-1 specific T cells on day 0 and day 14.
From (Bohnenkamp et al., submitted)
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Table 4.12: Autologous stimulation of T cells with DCs loaded with different peptides
DCs pulsed with FLU M1 Melan-A / Mart-1 Unpulsed
Inoculation [ 1mL ] 1.0 · 106 1.0 · 106 1.0 · 106
Total cell number d0 [-] 1.2 · 107 1.2 · 107 1.2 · 107
Total cell number d14 [-] 1.9 · 108 3.0 · 107 1.8 · 106
Maximum growth rate µmax [
1
h ] 2.6 · 10−2 2.1 · 10−2 -
Minimal generation time tmin [h] 27.2 32.5 -
Total CD8+ T cells [%] 36.7 63.2 -
Specific CD8+ T cells [%] 19.7 45.9 -
Expansion [x-fold] 4369 276 -
4.3.7 Autologous T Cell Response to Lysate-pulsed Dendritic Cells
In the previous experiments it has been demonstrated that fully matured lysate-pulsed den-
dritic cells can be obtained from a highly purified monocyte population. In addition, these
TNF-α and PGE2 matured DCs showed a high migratory capacity in several chemotaxis ex-
periments. Furthermore, a cryopreservation method of lysate-pulsed DCs in autologous plasma
has been established. Finally, peptide pulsed DCs efficiently stimulated autologous T cells in
an MHC class I restricted manner. In this section, the autologous T cell response to lysate-
pulsed dendritic cells is described, in which the previously established results are combined.
The parameters of this experiment are shown in table 4.13 on page 98.
The aim of this experiment was to demonstrate that lysate-pulsed dendritic cells can stimu-
late T cells in an MHC class II restricted manner and cross-prime T cells by presenting antigens
via the MHC class I pathway. Therefore, MCF-7 and MDA-MB-231 lysate-pulsed DCs were
utilized and co-cultered with autologous CD14-depleted PBMCs in the presence of IL-7 (first
week). Restimulation was performed weekly with addition of 20 UmL IL-2 and cells were adjusted
to a cell density between 5 · 105 and 1 · 106 1mL according to their proliferation. As a negative
control, TNF-α and PGE2 matured DCs without lysate pulsing were used. The scheme of the
autologous stimulation is shown in figure 4.38 on page 97.
A strong proliferative response in CD4+ and CD8+ T cells stimulated with lysate-pulsed
DCs was observed, whereas no proliferation was detected in PBMCs co-cultivated with unpulsed
DCs (see figure 4.39 on page 99). Two days after the 3rd stimulation the expression of CD25 (α-
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Figure 4.38: The scheme of the autologous stimulation of T cells with lysate-pulsed dendritic
cells. Dendritic cells were loaded with 100 µgmL tumor cell lysate and matured with TNF-α and
PGE2. Autologous T cells were co-cultivated for 7 days with DCs at a ratio of 10:1. Two re-
stimulations were performed after 7 and 14 days respectively (ratio T cells to DCs 20:1). T cells
were harvested on day 16 and analyzed as described.
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Table 4.13: The parameters of the experiments for the autologous stimulation of T cells
Cell density 1.0 · 106 1mL
Ratio DCs to T cells 1:10 (1st stimulation), 1:20 (2nd and 3rd stimulation)
Pulsing of DCs 100 µgmL lysate
Volume 12mL
Medium AIM V, serum-free
Donors three
Cultivation system Tissue culture flasks
IL-7 2400 UmL , 1
st day
IL-2 20 UmL , 7
th day
Feeding every 2nd day (medium + 20 UmL IL-2)
Cultivation time 16 days
chain of the IL-2 receptor), CD69 (c-type-lectin, early activation marker) and CD71 (transferrin
receptor) on T cells was analyzed. As demonstrated in figure 4.40 on page 100, CD4+ and CD8+
T lymphocytes were strongly activated with MCF-7 and MDA-MB-231 lysate-pulsed dendritic
cells. PBMCs co-cultured with TNF-α and PGE2 matured DCs without lysate pulsing showed
no expression of these surface proteins (data not shown). An IFN-γ secretion assay evidenced
the activation of CD4+ and CD8+ subsets of T cells. However, the population of IFN-γ secreting
cells was lower than the population of CD25, CD69 and CD71 expressing T cells.
MUC1 Specific T Cells Can be Recognized by Peptide MHC Class I Tetramers
Two days after the 3rd stimulation CD8+ T cells were analyzed with the F7 and M1.2 peptide
MHC class I tetramers. As a control, the irrelevant FLU M1 peptide MHC class I tetramer
was used. In the figures 4.41 (page 101), 4.42 and 4.43 (page 102) the frequency and the
corresponding expansion factor for one representative experiment out of three are shown. In
these experiments a selective expansion for the M1.2 epitope specific T cells and a higher
induction of these T lymphocytes by MCF-7 lysate-pulsed DCs compared with MDA-MB-231
lysate-pulsed DCs were observed. The expansion factor for M1.2 epitope specific T cells ranged
from 12-fold (MDA-MB-231 lysate) to 19-fold (MCF-7 lysate) respectively. The expansion of
all CD8+ T cells stimulated either with MCF-7 or MDA-MB-231 lysate pulsed dendritic cells
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Figure 4.39: Proliferation of T cells stimulated with MCF-7 or MDA-MB-231 lysate-pulsed
DCs. As negative control matured DCs (unloaded) were used.
was similar (see also table 4.14 on page 101). As demonstrated, the expansion of irrelevant FLU
M1 specific T cells was comparably low.
Lysate-pulsed DCs Induce Strong Th1 and Low Th2 Cytokine Profile
After 14 days of co-cultivation of T cells with matured DCs, peptide pulsed DCs and breast
carcinoma cell lysate-pulsed DCs, supernatants were harvested and analyzed for IL12p70, IFN-
γ, TNF-α, IL-2, IL-4, IL-5 and IL-10. IL-12p70 was not found in any of the supernatants (data
not shown). Nevertheless, a strong Th1 response was observed in all experiments (figure 4.44
on page 103). Melan-A / Mart-1, MDA-MB-231 lysate and MCF-7 lysate-pulsed DCs induced
17,232 pgmL , 15,740
pg
mL and 10,737
pg
mL IFN-γ respectively. In contrast, a much stronger T cell
response to the FLU M1 peptide was observed (51,100 pgmL IFN-γ). Control TNF-α and PGE2
matured DCs induced a very low IFN-γ response (960 pgmL). Interestingly, the Pan-DR binding
epitope PADRE alone induced an IFN-γ response similar to that of Melan-A / Mart-1 pulsed
DCs (17,232 pgmL IFN-γ), which were accompanied by the PADRE peptide. Low amounts of
TNF-α were detected in lysate-pulsed DC supernatants. The IL-2 concentrations correspond
to the level of cytokine supplement.
Analysis of the Th2 cytokines showed low amounts of IL-4 and IL-10, ranging between 10
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Figure 4.40: Breast carcinoma cell lysate-pulsed DCs induce the expression of CD25, the activa-
tion marker CD69, CD71 and IFN-γ secretion by T-helper cells and CTLs. Autologous T cells
were stimulated with DCs pulsed with either MCF-7 or MDA-MB-231 lysate and cultivated for
7 days with IL-7. T cells were restimulated twice in the presence of IL-2 and analyzed 48h after
the last stimulation. One representative experiment out of three is shown. Dot plots correspond
to gated CD3+ T cells. From (Bohnenkamp et al., in preparation)
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Table 4.14: Autologous stimulation of T cells with lysate-pulsed DCs
DCs loaded with MCF-7 lysate MDA-MB-231 lysate Unpulsed
Inoculation [ 1mL ] 1.0 · 106 1.0 · 106 1.0 · 106
Total cell number d0 [-] 1.2 · 107 1.2 · 107 1.2 · 107
Total cell number d16 [-] 4.8 · 108 5.7 · 107 1.8 · 106
Maximum growth rate µmax [
1
h ] 1.6 · 10−2 1.2 · 10−2 -
Minimum generation time tmin [h] 42.9 58.9 -
CD8+ T cells d0 [%] 17.6 17.6 -
CD8+ T cells d16 [%] 20.3 18.8 -
Expansion CD8+ T cells [x-fold] 4.6 5.1 -
Expansion F7 CD8+ T cells [x-fold] 8.1 7.5 -
Expansion M1.2 CD8+ T cells [x-fold] 18.9 12.0 -
Figure 4.41: Tumor lysate-pulsed DCs activate MUC1 specific T cells. Forty-eight hours after
the third stimulation T lymphocytes were stained with tetramers folded around the F7 and M1.2
peptide. FLU M1 was used as an irrelevant peptide. The negative control shows no staining.
Frequency of MUC1 and FLU M1 specific T cells after stimulation with MCF-7 pulsed DCs.
From (Bohnenkamp et al., in preparation)
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Figure 4.42: Frequency of MUC1 and FLU M1 specific T cells after stimulation with MDA-
MB-231 lysate-pulsed DCs. From (Bohnenkamp et al., in preparation)
Figure 4.43: Frequency corresponds to shown expansion factors. One representative donor out
of three is illustrated. From (Bohnenkamp et al., in preparation)
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Figure 4.44: Th1 (IFN-γ, TNF-α, IL-2) and Th2 (IL-4, IL-5, IL-10) cytokine profile analyzed
with the cytometric bead array after 14 days of co-cultivation of T cells with FLU M1 peptide (in
the presence of PADRE), Melan-A / Mart-1 (in the presence of PADRE), PADRE and lysate-
pulsed (MCF-7 and MDA-MB-231) DCs. Matured, unpulsed DCs did not induce cytokine
production of T cells. From (Bohnenkamp et al., in preparation)
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and 180 pgmL . No IL-4 was detected in FLU M1 stimulated experiments. Furthermore, high levels
of IL-5 were measured. FLU M1, Melan-A / Mart-1, MDA-MB-231 lysate and MCF-7 lysate-
pulsed DCs induced 585 pgmL , 1,516
pg
mL , 3,221
pg
mL and 1,705
pg
mL IL-5 respectively. Interestingly, the
lowest amounts for IL-4, IL-5 and IL-10 were observed in FLU M1 stimulated experiments.
The supernatants of Melan-A / Mart-1, PADRE (1,516 pgmL IL-5) and lysate-pulsed DCs showed
similar amounts of measured Th2 cytokines.
4.4 Transfer to Clinical Application
4.4.1 Cultivation of Dendritic Cells in a Fully Closed System
The developed protocol for the reproducible generation of dendritic cells in a high yield uses
standard tissue culture flasks for the cultivation. While this cultivation system yields dendritic
cells with a high purity and stimulatory capacity, it is labour intensive (requirement for four
tissue culture flasks per buffy coat) and bears the risk for contamination at various steps.
Therefore, a closed semi-automated system for the generation of monocyte-derived dendritic
cells is highly desirable.
The aim of this section is to describe the generation of DCs in a fully closed system. Mono-
cytes can be enriched by immunomagnetic beads utilizing the CliniMacs system from Miltenyi,
which can be operated semi-automated for the purification of cells from blood or leukapheresis
products. Subsequently, a cultivation bag is connected and filled with cells and the required
cultivation medium and supplements. Finally, the bag is centrifuged, cells are resuspended and
directly re-infused into the patient. The concept of the fully closed system is illustrated in figure
4.45.
Monocytes were enriched and inoculated into tissue culture flasks and hydrophobic teflon
bags with a cell density of 1.3 · 106 1mL in 30mL. After 6 days of differentiation, cells were
incubated with 100 µgmL lysate, TNF-α (1000
U
mL) and PGE2 (1
µg
mL) for additional two days. Table
4.15 summarizes the parameters for the comparison of the two different cultivation systems.
After 8 days of cultivation, dendritic cells were harvested and analyzed. The yield of mature
DCs (as defined by size of cells, morphology, surface antigen expression and apoptosis) cultivated
in tissue culture flasks and hydrophobic teflon bags was 90.2± 16.6% (n = 8) and 57.0± 8.1%
(n = 4) respectively and the number of apoptotic cells was 8.8±9.3% (n = 8) and 25.8±13.6%
(n = 4) respectively (figure 4.46, see also figure 4.18 on page 74). Without apoptosis analysis
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Figure 4.45: The concept of the generation of dendritic cells in a fully closed system.
Table 4.15: Experimental parameters for the generation of DCs in different cultivation systems
Cell densitiy 1.3 · 106 1mL
Donors four
Cultivation system tissue culture flask, teflon bag, 30mL volume
Medium X-VIVO 15
GM-CSF 400 UmL
IL-4 2000 UmL
Maturation stimulus 100 µgmL lysate, TNF-α (1000
U
mL), PGE2 (1
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
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Figure 4.46: Yield of lysate-pulsed and TNF-α and PGE2 matured dendritic cells cultivated
either in tissue culture flasks or teflon bags. Results are from 8 (tissue culture flasks) or 4
(teflon bags) different donors respectively and presented as mean ± standard deviation. Shown
are viable (AV− / PI−) and apoptotic (AV+ / PI−) cells.
Figure 4.47: Activation of T cells (CD3) was assessed by CD25 (α-chain of the IL-2 receptor)
staining after 4 days of co-cultivation.
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Figure 4.48: Phenotypical analysis of matured lysate-pulsed DCs either cultivated in tissue
culture flasks or teflon bags. Shown are results of surface antigen expression as indicated as
mean ± SD from 4 independent experiments.
Figure 4.49: Activation of T cells (CD3) was assessed by CD71 (transferrin receptor) staining
after 4 days of co-cultivation
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the yield of matured DCs cultivated in tissue culture flasks and hydrophobic teflon bags was
66.3± 13.6% and 41.9± 6.0% respectively.
Nevertheless, the phenotypical analysis of both tissue culture flask and teflon bag DCs
demonstrated no difference in surface marker expression. The stimulatory molecules HLA-
A,B,C (MHC class I) and HLA-DR (MHC class II), the co-stimulatory surface proteins CD80
and CD86 and the maturation marker CD83 were highly up-regulated, which is shown in figure
4.48 on page 107. The surface protein CD1a was expressed in a medium level and CD14 was
not found on matured dendritic cells.
In contrast, slight differences were found in an allostimulatory T cell response in a mixed
leukocyte reaction. Both the analysis of CD25 and CD71 activation marker expression on T
cells after 4 days of co-cultivation with DCs at different ratios (1:10, 1:20 and 1:40 respectively)
indicated small differences in the stimulatory capacity of DCs cultivated in tissue culture flasks
or teflon bags (figures 4.47 on page 106 and 4.49 on page 107). The number of positive T cells
stimulated with DCs cultivated in tissue culture flasks were superior to the teflon bag DCs.
4.4.2 Dendritic Cells from Breast Cancer Patients
So far, in all described experiments of this thesis blood from healthy donors were used. Con-
sequently, an important question has to be addressed: Can fully matured dendritic cells be
obtained from breast cancer patients? For that reason, several experiments were performed
utilizing patients’ blood for the generation of monocyte-derived dendritic cells with the stan-
dardized protocol.
From six different patients who were under treatment in the Breast Cancer Unit at Guy’s
Hospital in London, UK, written informed consent was obtained after the nature and conse-
quences of the study were fully explained. Blood donations (volume of 25mL) were taken from
each patient and directly processed. The history from each patient is summarized in table 4.16
on page 109. Furthermore, the collected number of PBMCs and the yield of matured dendritic
cells are illustrated.
The number of matured dendritic cells generated from 25mL of blood from breast cancer
patients was 3.5 · 106 ± 1.0 · 106 from 6 different donors, which correspond to a yield (as defined
by size of cells, morphology and surface antigen expression) from PBMCs and monocytes of
7.6± 1.8% and 59.4± 17.0% respectively (compare table 4.6 on page 68, the yield of matured
DCs from healthy donors was 66.3± 13.6%). The apoptosis of monocytes or dendritic cells was
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Table 4.16: The history from breast carcinoma patients who participated in the study for testing
the quality and quantity of matured DCs generated with the standardized protocol
LOG Time of Number of Number of
FILE treatment PBMCs matured DCs
[extracts] [years] [-] [-]
Patient 1 Mastectomy 12 4.0 · 107 3.2 · 106
Capecitabine1
Docetaxel1
Tamoxifen2
Patient 2 Radiotherapy / Biopsy 30 4.0 · 107 2.8 · 106
Tamoxifen2
Vaccinia MUC13
Docetaxel1
Patient 3 Radiotherapy 11 5.0 · 107 5.4 · 106
Tamoxifen2
Patient 4 Primary Breast Cancer 0 5.0 · 107 3.7 · 106
FEC1,4
Patient 5 Irridium Inplant 18 5.0 · 107 3.4 · 106
Mastectomy
Tamoxifen2
Docetaxel1
Patient 6 Radiotherapy 9 3.9 · 107 2.1 · 106
Biopsy
Tamoxifen2
MEAN ± SD 46.0± 5.6 · 106 3.5± 1.0 · 106
Yield from
PBMCs [%] 7.6± 1.8
Monocytes [%] 59.4± 17.0
Viability of DCs [%] 95.0± 3.0
1Chemotherapy, 2Steroid endocrine therapy, 3Immunotherapy, 4S-Fluorouracil Epirubicin Cy-
clophosphamide
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Figure 4.50: Phenotypical analysis of TNF-α and PGE2 matured dendritic cells from breast
cancer patients. Shown are results of surface antigen expression as indicated as mean ± SD
from 6 independent experiments.
not determined during this experiment.
After harvesting the dendritic cell population on day 8, the phenotypical analysis showed
no differences of DCs from breast cancer patients compared to the cells from healthy donors
(see also figure 4.14 on page 68). As illustrated in figure 4.50, the stimulatory molecules HLA-
A,B,C (MHC class I) and HLA-DR (MHC class II), the co-stimulatory surface proteins CD80
and CD86 and the maturation marker CD83 were highly up-regulated. The surface molecule
CD1a was weakly expressed, while the receptor for LPS-LBP CD14 was not found on DCs.
Chapter 5
Discussion
5.1 The Generation of Dendritic Cells: Clinical Applica-
bility
The aim of this study was to determine optimal conditions for the generation of monocyte-
derived dendritic cells by developing a standardized, easy to use and reproducible protocol that
yields in a sufficient number of DCs for immunotherapeutical vaccination trials. Within this
study a non-feeding protocol in serum-free conditions was accomplished that is in accordance
with GMP requirements and therefore applicable for clinical use. The results of the development
of the optimized protocol are illustrated in table 5.1 on page 112.
Culture of immunomagnetic bead enriched monocytes using serum-free conditions for 6
days resulted in immature dendritic cells with low levels of CD83 expression. Final maturation
was induced for additional 2 days by the pro-inflammatory cytokines TNF-α, IL-1β and IL-
6 supported by PGE2 (Jonuleit et al., 1997) or TNF-α and PGE2 (Kalinski et al.,
1998), both of which resulted in the up-regulation of high levels of the stimulatory molecules
HLA-A,B,C (MHC class I) and HLA-DR (MHC class II), the co-stimulatory molecules CD40,
CD80 and CD86, the intercellular adhesion molecule ICAM-1, the maturation marker CD83
and the chemokine receptors CXCR4 and CCR7. CD1a, an MHC class I analogue molecule that
presents lipids, showed medium levels of expression, whereby CD14 (receptor for the LPS-LBP
complex) was not found on matured DCs.
Using this protocol a yield of 66.3± 13.6% of fully matured dendritic cells from inoculated
monocytes (viable and apoptotic) from healthy donors with a viability of 93.4 ± 5.9% were
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Table 5.1: The results of the development of the optimized protocol for the generation of
monocyte-derived dendritic cells
Enrichment of monocytes Immunomagnetic beads
Cell densitiy 1.3 · 106 1mL monocytes
Cultivation system 75cm2 tissue culture flasks, 30mL volume
Fully closed system Hydrophobic teflon bag, up to 500mL volume
Medium X-VIVO 15, serum-free
GM-CSF 400 UmL
IL-4 2000 UmL
Maturation stimulus TNF-α (1000 UmL), PGE2 (18
µg
mL)
Lysate pulsing Lysate (100 µgmL), TNF-α (1000
U
mL), PGE2 (1
µg
mL)
Time (differentiation / maturation) 6 days / 2 days
In accordance with GMP requirements YES
obtained. It was demonstrated that feeding of the cells is not necessary and that it is sufficient to
add only 400 UmL GM-CSF and 2000
U
mL IL-4 at the beginning of the cultivation. The comparison
of the results described in this thesis with published data from various reports in literature is
shown in table 5.2 on page 113. Nearly all published protocols used either feeding or serum and
resulted in a lower yield.
Moreover, the data clearly demonstrate that under serum-free conditions the cytokine-
cocktails consisting of either TNF-α (1000 UmL), IL-1β (1000
U
mL), IL-6 (1000
U
mL) and PGE2
(1 µgmL) or TNF-α (1000
U
mL) and PGE2 (18
µg
mL), a simplified cocktail with just two components,
are sufficient to induce the final maturation of immature DCs into mature, homogenous and
immunostimulatory dendritic cells.
For the generation of dendritic cells under GMP requirements the usage of a fully closed
system from the blood donation until the re-infusion of cells into the patient would facilitate
the handling and decrease potential contamination sources. For that reason, dendritic cells
were generated in teflon bags and compared with DCs cultivated in tissue culture flasks. The
yield of DCs from teflon bags and tissue culture flasks was 41.9 ± 6.0% and 66.3 ± 13.6%
respectively (yield of DCs from all viable monocytes without apoptosis analysis; for comparison
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Table 5.2: Comparison of the results described in this thesis with data of the generation of DCs
reported in various publications
Name Year Enrichment Serum Feeding Yield∗
Babatz et al. 2003 Magnetic beads 1% YES 12.1%
Dietz et al. 2000 Magnetic beads 2% YES 18.3 ± 6.3%
Felzmann et al. 2003 Magnetic beads NO YES 8.0 ± 3.0%
Meyer-Wentrup et al. 2003 Magnetic beads 1% YES 41.0 ± 4.0%
Motta et al. 2003 Magnetic beads 1% YES 20.7 ± 4.6%
Padley et al. 2001 Magnetic beads 1% YES 30.3 ± 6.4%
Pullarkat et al. 2002 Magnetic beads NO NO 9.2 ± 5.2%
Ratta et al. 2000 Magnetic beads 10% YES 4.8 ± 1.3%
Berger et al. 2002 Attachment 2% YES 19.9 ± 9.6%
Goxe et al. 2000 Elutriation 2% NO 48.3 %
Tissue culture flask Thesis Magnetic beads NO NO 66.3 ± 13.6%
Teflon bag Thesis Magnetic beads NO NO 41.9 ± 6.0%
∗Yield: Yield of viable dendritic cells from inoculated monocytes
with the results reported in various publications; see table 5.2). At first sight, the decrease in
yield of about 37% might be disappointing, which was caused by the induction of apoptosis.
Nevertheless, it was proven that the quality of matured and lysate-pulsed DCs were nearly
similar to tissue culture flask DCs, as analyzed by phenotype and mixed leukocyte reaction.
By comparison, Pullarkat et al. (2002) generated dendritic cells in gas-permeable culture
bags, which yielded in 9.2 ± 5.2% matured DCs. Thus, even in teflon bags, the generation of
DCs using the protocol developed in this study is highly effective compared with published
data.
For immunotherapeutical trials using dendritic cell based vaccines various amounts of ma-
tured dendritic cells have been used for different numbers of infusions into the patient. Never-
theless, the average total number of utilized dendritic cells was 3.2 ·107 that have been supplied
in 3 up to 10 infusions. Therefore, the number of 5.8±1.2·107 (average amount of DCs generated
from 500mL of blood, see table 4.6 on page 68) of fully matured dendritic cells from healthy
donors provide the required number for vaccination trials. In table 5.3 on page 115 recently
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Figure 5.1: The phenotype of matured dendritic cells from either breast cancer patients’ blood
or blood from healthy donors. Shown are results from 6 (breast cancer patients) and 8 (healthy
donors) different experiments and illustrated as mean ± standard deviation.
published data from several clinical trials using dendritic cell based vaccines are summarized
and compared with the results of this thesis. Interestingly, the number of dendritic cells from
breast cancer patients out of 25mL of blood was 3.5± 1.0 · 106, which corresponds to a theoret-
ical number of 7.0± 2.0 · 107 from 500mL of blood. The higher number of fully matured DCs
from patients’ blood might be due to the usage of fresh blood compared with 12h to 18h old
buffy coats in the case of healthy donors.
Additionally, the flowcytometrical analysis of matured dendritic cells from healthy donors
and breast cancer patients demonstrated no difference in the level of expression of important
surface molecules, such as the stimulatory molecules MHC class I (HLA-A,B,C), MHC class II
(HLA-DR) and CD1a, the co-stimulatory molecules CD80 and CD86, the maturation marker
CD83 and the receptor for the LPS-LBP complex CD14 (see figure 5.1). In sum, a high yield of
fully matured monocyte-derived dendritic cells from patients’ blood were obtained regardless
the type of previous cancer therapies and the duration of treatment.
Stimulation of allogeneic naive T cells in a mixed leukocyte reaction led to high proliferation
with either cytokine cocktail. Production of IFN-γ was significantly induced, while no effect
on the production of IL-4 or IL-12p70 was observed. These findings are in agreement with
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Table 5.3: Published clinical trials and the number of total dendritic cells used for vaccination
Name Year Antigen Average No. Total
No. of DCs of vacc.∗ No. of DCs
Brossart et al. 2000 Her-2 / neu 5.9 · 106 5 3.0 · 107
MUC1
Chang et al. 2002 Lysate∗ / KLH∗ 1.0 · 107 6 6.0 · 107
Dhodapkar et al. 2000 FLU M1 4.0 · 106 3 1.2 · 107
KLH∗ / TT∗
Geiger et al. 2001 Lysate∗ / KLH∗ 1.0 · 107 3 3.0 · 107
Gitlitz et al. 2003 Lysate∗ 6.0 · 106 4 2.4 · 107
Hoeltl et al. 2002 Lysate∗ / KLH∗ 1.0 · 107 6 6.0 · 107
Cell line A-498
Nestle et al. 1998 Lysate∗ / KLH∗ 1.0 · 106 10 1.0 · 107
Peptides / KLH∗
Thurner et al. 1999a Mage-3A1 peptide 5.5 · 106 5 2.8 · 107
TT∗ / turberculin
Mean 3.2 · 107
Thesis 2004 - - - 5.8± 1.2 · 107
(Buffy coat, 500mL)
Thesis 2004 - - - 3.5± 1.0 · 106
(Patients, 25mL)
Theoretically 2004 - - - 7.0± 2.0 · 107
(Patients, 500mL)
∗Vacc.: vaccination; helper antigens: KLH: keyhole limpet hemocyanin; TT: tetanus toxoid;
Lysate: autologous tumor cell lysate
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Jonuleit et al. (1997), who demonstrated that the addition of PGE2 to a cocktail of TNF-
α, IL-1β and IL-6 led to higher IFN-γ production in an allogeneic primary stimulation. They
also observed, that neither CD4+ nor CD8+ T cells produced IL-4 or IL-10, indicating that
these dendritic cells could not support the development of Th2 cells. Moreover, three studies
showed recently that PGE2 regulates the migratory capacity of monocyte-derived dendritic
cells (Luft et al., 2002; Scandella et al., 2002, 2004) and that these migratory-
type dendritic cells produce lower levels of cytokines (including IL-12p70) and induce IFN-γ
production of T cells in mixed leukocyte reactions (see also chapter 5.3). These conclusions were
confirmed by several clinical investigations using monocyte-derived dendritic cells matured with
the cytokine-cocktail utilized in this study (TNF-α, IL-1β, IL-6, PGE2), which induced potent
T cell immune responses in patients undergoing immunotherapy (Schuler-Thurner et al.,
2002; Dhodapkar et al., 2001). In contrast, Kalinski et al. (1998) reported that DCs
matured in the additional presence of PGE2 bias naive T-helper cell development towards Th2
cells. However, this may be caused by different cultivation parameters including FCS in the
cultivation setup.
In conclusion, it has been shown that this simplified, easy to use protocol, which circumvents
the necessity of feeding and the usage of serum, results in a sufficient number of dendritic cells
for immunotherapeutical vaccine trials. Furthermore, this protocol can be used in a fully closed
system, which results in a decreased number of DCs but facilitates the handling and reduces the
risk of contaminations. Moreover, this procedure, developed with blood from healthy donors,
is usable with breast cancer patients’ blood without compromises regarding yield or quality of
fully matured dendritic cells.
5.2 Apoptosis of Monocytes
Currently, monocyte-derived dendritic cells are becoming widely used as cell vaccines for cancer
treatment (Gabrilovich 2002; Schuler et al., 2003). The requirement for optimized and
standardized protocols for the generation of dendritic cells in a large-scale has led to several
protocols (see chapter 2.4). The present study was designed to determine why the yield of
monocyte-derived dendritic cells is lower than 70%. Additionally, it focusses on the fate of
monocytes during differentiation to matured dendritic cells.
Buffy coats from healthy donors were used, processed by immunomagnetic-bead selection
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to obtain highly enriched CD14+ cells, which were analyzed for apoptosis. In agreement with
previous observations, monocytes were partly apoptotic after enrichment. Fahy et al. (1999)
reported 25 ± 1.1% (n = 3) of annexin V positive cells after enrichment by clumping. In the
present study an average of 37.8 ± 11.1% (n = 8) of the monocyte population was found to
be positive for annexin V. The higher percentage might be caused by the quality or age of
the utilized buffy coats (12h to 18h) or the method of enrichment of the cells. However, no
difference after the immunomagnetic-bead selection compared with unselected cells was seen
(data not shown).
These data were based on the flow cytometric detection of PS expression by discriminat-
ing intact cells (annexin V −/PI−), early apoptotic cells (annexin V +/PI−) and necrotic cells
(annexin V +/PI+), which has been shown to be a reliable method (Vermes et al., 1995;
Lecoeur et al., 1997). Under viable conditions the molecular architecture of biological mem-
branes is highly asymmetric (Bevers et al., 1989). Typically, phospatidylserine is almost
completely absent in the outer leaflet of the plasma membrane. During programmed cell death
various biological alterations take place including phospatidylserine redistribution on the outer
leaflet (Vermes et al., 2000). Van Engeland et al. (1998) reported that at the early
stage of apoptosis membrane integrity has not been compromised and no nuclear alterations
can be observed but PS exposure is detectable.
To further characterize the fate of cells during differentiation to matured dendritic cells the
non-attached population was analyzed. After 24h more than 80% of the suspension cells (53%
of initial apoptotic cell number) were annexin V positive, which correlated with most of the
viable cells becoming attached to the surface of the tissue culture flask. In contrast, after 6 days
almost all immature dendritic cells, now in suspension, were viable and represented an average
yield of 91.2 ± 26.8% (n = 8) of inoculated, non-apoptotic monocytes. These results indicate
that nearly all viable, non-apoptotic monocytes differentiated to immature dendritic cells. The
yield of matured dendritic cells was 90.2 ± 16.6% (n = 8) after 8 days (see figure 5.2). Cells,
still attached on day 6, became suspension cells during maturation, resulting in a higher total
cell number (viable and apoptotic cells).
An overall cell loss of 40% of highly purified monocytes during the first 24h has been
observed when differentiating these cells to macrophages (Andreesen et al., 1983, Brug-
ger et al., 1991, Lund et al., 2001). Lund et al. (2001) speculated that monocytes
undergo programmed cell death as a combined effect of in vivo aging and in vitro stress condi-
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Figure 5.2: Yield of immature and TNF-α and PGE2 matured dendritic cells. Results are from
8 different donors and presented as mean ± standard deviation. Shown are viable (AV− / PI−)
and apoptotic (AV+ / PI−) cells. From (Bohnenkamp et al., submitted)
tions. The first 6h seemed to be critical for the choice between death and survival, with only
the survivors developing into macrophages (Lund et al., 2001). Furthermore PS exposure,
which is one of the ’eat me’ signals at the surface of apoptotic cells, results in phagocytosis
(Reutelingsperger et al., 2002). In agreement with the results of this thesis, Lund et
al. (2002) demonstrated that only a few signs of cell remnants are found. The results of this
study also showed that GM-CSF and IL-4 protected monocytes from further apoptosis. Fahy
et al. (1999) concluded that monocytes undergo spontaneous programmed cell death in the
absence of inflammatory stimulation.
Maturation of monocyte-derived dendritic cells generated by the previously described pro-
tocol (Bohnenkamp and Noll, 2003) was monitored by up-regulation of stimulatory and
co-stimulatory molecules as well as the CD83 maturation marker (Zhou and Tedder, 1995).
The CD83 expression in all donors was higher than 85% (n = 8). Analysis of the stimulatory
capacity in an allogeneic T cell response (Nguyen et al., 2003) and in the MHC class I re-
stricted autologous stimulation demonstrated the immunological functionality of the generated
matured dendritic cells.
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In conclusion, it was shown that apoptosis plays an important role in the generation of
monocyte-derived dendritic cells. For calculation of the yield of any cell population only viable,
non-apoptotic cells should be evaluated. It was confirmed that more than 90% of viable mono-
cytes differentiated to fully matured dendritic cells. Thus, the starting population of monocytes
determines the yield of DCs, which is consistently 90% of viable monocytes. Further investiga-
tion could focus on the effect of dendritic cell generation in the absence of apoptotic monocytes.
Additionally, the analysis of apoptosis of dendritic cells used in clinical vaccination approaches
should be generally considered because cells, presenting PS on their surface, would be eliminated
and less effective.
5.3 Induction of MUC1 Specific T Lymphocytes
The goal of this study was to evaluate a potential breast carcinoma cell vaccine for controlling
and enhancing tumor associated antigen presentation, which is a critical regulatory element for
the induction of a cellular immune response (Gunzer and Grabbe, 2001). A reproducible
preparation method for tumor cell lysates by sonication at low temperatures was developed
to avoid protein alteration by proteases or phosphatases ensuring that the tumor associated
proteins that are loaded onto dendritic cells for processing were unaffected by the preparation
method. For induction of maturation, DCs were pulsed with 100 µgmL of protein combined with
the adjuvants TNF-α and PGE2. These PGE2 matured DCs migrated towards the chemokines
CXCL12 and CCL19, which is critical for induction of T cells in lymph nodes. Moreover, it
has been shown that lysate-pulsed DCs can be cryopreserved without affecting stimulatory
properties. The exogenous proteins were effectively processed by DCs and presented in the
context of MHC class I and MHC class II, which was evidenced by cross-priming of CD8+
cytotoxic T cells and a strong CD4+ Th1 response. The activation of MUC1 specific cytotoxic
T cells was demonstrated by tetramer analysis with the epitopes M1.2 and F7. The results of
this study are presented in table 5.4 on page 120.
The up-regulation of the chemokine receptor CCR7 on dendritic cells is crucial for their
homing to secondary lymphoid organs, e.g. lymph nodes where the CCR7 ligand CCL19 is
expressed. During infections, high levels of TNF-α, IL-1β, GM-CSF and PGE2 are secreted by
monocytes, macrophages and endothelial cells (Luft et al., 2002). These pro-inflammatory
mediators directly act on immature dendritic cells being present in inflamed tissues, resulting in
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Table 5.4: The results of the study investigating the induction of MUC1 specific T lymphocytes
primed by breast carcinoma cell lysate-loaded dendritic cells.
Chapter Results
4.3.1 A reproducible and simple lysate preparation method was developed, which
avoids proteolytic reactions to solubilize proteins without degradation
4.3.2 Immature DCs efficiently endocytoze dextran, LPS and microspheres
4.3.3 Fully matured DCs were obtained after maturation with
100 µgmL of protein combined with the adjuvants TNF-α and PGE2
Dendritic cells demonstrated a high allostimulatory capacity in MLR
Yield of lysate-pulsed DCs: 75.6± 12.3% (n = 3) and 91.8± 8.2% (n = 6)
(MDA-MB-231 and MCF-7 lysate-pulsed DCs respectively)
4.3.4 TNF-α and PGE2 matured DCs up-regulated CXCR4 and CCR7
Matured DCs showed high migration towards CXCL12 and CCL19
4.3.5 Lysate-loaded DCs can be cryopreserved in autologous plasma + 10% DMSO
Yield: 85.3± 9.4%, Viability: 89.3± 6.0%, (n = 6)
4.3.6 Matured DCs effectively induce MHC class I restricted T cell responses
Expansion factors: 4369-fold (FLU M1), 276-fold (Melan-A / Mart-1)
Induction of IFN-γ producing Th1 cells:
51,100 pgmL (FLU M1), 17,232
pg
mL (Melan-A / Mart-1)
Induction of IL-5 producing Th2 cells:
585 pgmL (FLU M1), 1,516
pg
mL (Melan-A / Mart-1)
4.3.7 Lysate-pulsed DCs cross-prime autologous T cells analyzed by MUC1 epitopes
Expansion factors (MDA-MB-231): 7.5-fold (F7), 12.0-fold (M1.2)
Expansion factors (MCF-7): 8.1-fold (F7), 18.9-fold (M1.2)
Induction of IFN-γ producing Th1 cells:
15,740 pgmL (MDA-MB-231), 10,737
pg
mL (MCF-7)
Induction of IL-5 producing Th2 cells:
3,221 pgmL (MDA-MB-231), 1,705
pg
mL (MCF-7)
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the expression of CCR7. In several studies it has been reported that PGE2 is crucial for the up-
regulation of CCR7 and the migration towards its ligands (Luft et al., 2002; Scandella
et al., 2002, 2004). Furthermore Scandella and co-workers (2004) demonstrated that
CXCR4 mediates migration of monocyte-derived dendritic cells to CXCL12 is dependent on
the presence of PGE2. Neither LPS nor CD40 ligand induces migratory dendritic cells (Luft
et al., 2002; Scandella et al., 2002). Additionally, immature DCs expressing CXCR4 do
not migrate substantially to the CXCR4 binding pro-inflammatory chemokine CXCL12 (Luft
et al., 2002). Thus, the presence of PGE2 for the maturation seems to be essential to induce
migratory dendritic cells.
Exogenous antigens are internalized by different pathways: dendritic cells endocy-
tose antigen by receptor mediated phagocytosis and receptor-independent macropinocytosis
(Guermonprez et al., 2002). Wether lysate-pulsed dendritic cells efficiently cross-present
antigens via the MHC class I pathway is a matter of discussion. However, it has been shown
using antigens bound to latex beads that they can be processed by both phagocytosis and
macropinocytosis and then cross-presented on dendritic cells (Shen et al, 1997; Reis e
Sousa and Germain, 1995). Recently, it was suggested that cross-presentation is controlled
by the existence of phagosomal compartments, generated through fusion of the endoplasmatic
reticulum with endolysosomal vesicles (Lize´e et al., 2003). DC uptake of soluble antigen
is only via macropinocytosis (Watts, 1997). Comparative studies using apoptotic cells or
necrotic cell-lysates as a source of whole tumor cell antigens, have demonstrated no difference
in the efficiency of either method to prime an anti-tumor immune response (Lambert et al.,
2001; Kotera et al., 2001). Here, it was validated that tumor associated MUC1 was ef-
fectively processed and cross-presented by mature dendritic cells by their ability to generate
MUC1 specific T cells. The expansion of M1.2 specific T cells was higher compared with T
cells activated by the F7 epitope, which was probably caused by the phenomenon of dominance
between different epitopes (Kedl et al., 2003). Thus, the rather simple method of lysate
preparation in contrast to apoptotic cell generation seems to be the technique of choice to
deliver tumor associated antigens to the MHC class I and MHC class II pathway. More impor-
tantly, the obtainment of viable tumor cells from primary breast carcinomas could prove to be
difficult.
Tumor cell lysate is generally prepared by repetitive freeze and thaw cycles. However, the
amount of protein, the equivalent ratio of tumor cells to dendritic cells and the maturation
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inducing adjuvant, which promotes the distinct phenotype, are currently under extensive in-
vestigation. In this study it was confirmed that 100 µgmL of tumor cell lysate, which is equivalent
to a ratio of one tumor cell to one DC, with the adjuvants TNF-α (1000 UmL) and PGE2 (1
µg
mL)
administered for two days resulted in a fully mature phenotype with effective migratory, al-
lostimulatory, MHC class I and MHC class II stimulatory capacity. However, the maturation
adjuvants direct DCs to a non-cytokine producing type, as no IL-12p70, IL-4 or IL-10 was
detected after two days of activation. Furthermore, no IL-12p70 was detected during stimula-
tion of T cells. Phenotypically identical DCs may differ in their ability to produce cytokines
to induce either Th1 or Th2 cells, depending on the inflammatory cytokine environment that
induces their maturation (Hilkens et al., 1997; Kalinski et al., 1998). The presence of
PGE2 during the maturation development of DCs led to the generation of IL-12p70 deficient
cells (Kalinski et al., 1997). After triggering of DCs by bacterial stimuli, IL-12p70 is pro-
duced only transiently, during a narrow time window of about 10h to 18h and is refractory to
further stimulation (Langenkamp et al., 2000). Therefore, for efficient IL-12p70 production
dendritic cells have to be vaccinated at a time point when they become mature cells, in other
words these dendritic cells would be not fully mature with regard to up-regulation of surface
molecules like co-stimulatory signals and the maturation marker CD83.
In contrast, Schnurr et al. (2001) showed that DCs pulsed with 120 µgmL protein (equiva-
lent to 1.3 tumor cells to DCs) and matured with TNF-α (1000 UmL) and PGE2 (1
µg
mL) produced
IL-12 during stimulation of T cells. It was not clear whether the monomeric IL-12p40 or the
bioreactive IL-12p70 was analyzed. Although it was reported that PGE2 induces the inactive
IL-12p40 (Rieser et al., 1997), it is not accompanied by the production of the bioreactive
heterodimer IL-12p70 (Kalinski et al., 1998). However, several studies have reported the
induction of anti-tumor immunity by DCs loaded with tumor lysate at various concentrations
in the absence of IL-12p70. Bachleitner-Hofmann et al. (2002) used 100 µgmL and TNF-α
for 12h, Herr et al. (2000) incubated lysate and the cytokines TNF-α, IL-1β, IL-6 and
PGE2 for 2 days, Kass et al. (2003) pulsed matured DCs (TNF-α, IL-1β and PGE2) with
lysate and the cationic lipid DOTAP for protein uptake, Thumann et al. (2003) pulsed DCs
with up to 1mgmL ovalbumin and the cytokines TNF-α, IL-1β, IL-6 and PGE2 for 2 days and
Wen et al. (2002) triggered DCs with 100 µgmL protein for 6 days. In contrast, Vegh and
Mazumber (2003) utilized protein (equivalent to one tumor cell to one DC), LPS and IFN-γ
and was able to induce IL-12p70 during the first 24h following maturation of DCs.
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The selective differentiation of either subset of T helper cells is established during priming
and depends on various factors, namely the cytokine environment, the dose of the antigen,
strength of antigenic stimulation, duration of the T cell receptor engagement and the nature
and quantity of co-stimulatory molecules (Constant and Bottomly, 1997; Kapsenberg,
2003; Langenkamp et al., 2000; O’Garra and Arai, 2000; Sallusto and Lanza-
vecchia, 2002). The T cell stimulation and Th1 and Th2 polarization require three den-
dritic cell derived signals. The first signal is the antigen-specific signal, the second is given
by co-stimulatory molecules and the third, the polarizing signal, is mediated by soluble or
membrane-bound factors (Kapsenberg, 2003). The breast carcinoma lysate-pulsed dendritic
cells generated did not deliver a third signal by soluble mediators such as the analyzed cytokines.
As a consequence, the polarization of the strong Th1 cell response may be mediated by the dose
of antigen presented on the surface of the DCs and the quantity of co-stimulatory signals. In
mouse experiments it was demonstrated that high doses of soluble antigen favored a Th1 cell
response (reviewed in Constant and Bottomly, 1997). However, as it was demonstrated
by induction of MHC class I restricted T cell responses with the FLU M1 and Melan-A / Mart-1
peptide, the kind of antigen and response (memory or naive) determines the polarization.
In the current study several important parameters were tested to evaluate the effective puls-
ing with breast carcinoma cell lysate of dendritic cells. The migratory and immunostimulatory
capacity of matured dendritic cells were demonstrated and confirmed that lysate loaded DCs
are able to effectively cross-prime CD8+ cytotoxic T cells. The cytokine profile and the polariza-
tion of T helper cells suggest that a high antigen dose and quantity of co-stimulatory molecules
on DCs is able to induce a strong Th1 T cell response, even in the absence of a polarizing third
signal.
5.4 Final Observation
Dendritic cells were first discovered in 1973 by Ralph Steinman and are now known for over 30
years. The concept that DCs are the initiators of primary immune responses were proven and
it has become evident that these unique cells have a dual role as controllers of both immunity
and tolerance.
Currently, many in vitro studies and in vivo clinical trials have reported promising results,
which includes monitored T cell responses and tumor regressions in some cancer patients.
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Nevertheless, as long as the tumor cell escape from immune surveillance and the active role
of dendritic cells in tolerance is not fully understood, effective immunotherapeutical vaccine
strategies need still to be developed.
One crucial factor for getting new insights into the immunobiological function of the body’s
defense system may be a standardized administration of dendritic cell based cancer vaccines,
which is followed by close immunomonitoring of patients. Perhaps this work may contribute to
the further understanding of the concerted interplay of immunity and tolerance.
Chapter 6
Summary
Monocyte-derived dendritic cells (DCs) are currently under extensive evaluation as cell vaccines
for cancer treatment. The requirement for large-scale cell products demands optimized and
standardized protocols. This study demonstrates that highly viable DCs (93.4± 5.9%) can be
produced from CD14+ monocytes enriched via immunomagnetic beads in a high yield (66.3±
13.6%) and purity (95.4± 2.1%) with X-VIVO 15, 400 UmL GM-CSF and 2000 UmL IL-4 without
serum and feeding. For the maturation of DCs different cytokine combinations (TNF-α, IL-1β,
IL-6, PGE2 and TNF-α, PGE2) were compared. In both cases cells expressed typical surface
molecules of mature DCs and induced high proliferative responses in mixed leukocyte reactions
which led to IFN-γ producing T lymphocytes. Comparison of dendritic cells from blood from
healthy donors with breast cancer patients’ blood demonstrated no differences regarding yield
or quality of fully matured dendritic cells.
Furthermore, this study aimed to investigate if the yield is determined by the prop-
erties of the starting population of inoculated monocytes. CD14+ cells were enriched by
immunomagnetic-bead selection and analyzed for apoptosis by an annexin V / propidiumio-
dide assay. It was demonstrated that 37.8±11.1% (n = 8) of freshly isolated monocytes from
buffy coats of healthy donors underwent programmed cell death. Further analysis of the fate
of apoptotic cells during differentiation suggested phagocytosis. The yield of viable matured
dendritic cells from non-apoptotic monocytes was calculated to be 90.2±16.7%. These results
indicate that the yield of dendritic cells is mainly influenced by the percentage of apoptotic
cells in the inoculum, and impact on DC generation for clinical application.
For cancer immunotherapy the loading of DCs with whole tumor cell lysate preparations
represents a simple and promising approach to utilize all potential known and unknown tumor-
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associated antigens (TAAs) and to circumvent the disadvantages like HLA-mismatching and
the requirements for known TAAs. For this reason it is important whether lysate-pulsed DCs
efficiently cross-prime cytotoxic T cells (CTLs) and induce a strong Th1 cell response. Ad-
ditionally, this was compared to FLU M1 and Melan-A / Mart-1 peptide pulsed DCs. As a
model system breast carcinoma cell lysate from either MCF-7 or MDA-MB-231 cells express-
ing the TAA MUC1 were chosen. The epithelial mucin MUC1 is a large molecular weight
O-glycosylated protein, which is overexpressed in the majority of breast, ovarian and other
epithelial malignancies and represents a promising target in cancer immunotherapy. A simple
lysate preparation method was developed to solubilize all cell proteins without degradation. For
loading of monocyte-derived dendritic cells, 100 µgmL of breast carcinoma cell lysate was used,
accompanied by an adjuvant consisting of tumor necrosis factor-α and Prostaglandin-E2. T
cells were co-cultivated with lysate or peptide pulsed DCs and were restimulated weekly. Be-
fore cultivation, and after the 3rd stimulation, tetramer frequencies for the MUC1 epitopes F7
and M1.2 as well as for the FLU M1 and Melan-A / Mart-1 epitopes were determined. After
stimulation with lysate, higher frequencies for M1.2 specific T cells were observed compared
with the F7 epitope. Furthermore, the expansion factor for M1.2 specific T cells that had been
stimulated with MCF-7 lysate-pulsed DCs were found to be up to 19-fold. The analysis of typ-
ical Th1 / Th2 cytokines (IFN-γ, TNF-α, IL-12p70, IL-2, IL-4, IL-5, IL-10) revealed a strong
Th1 response: up to 50,000 pgmL IFN-γ were determined in the supernatants of the stimulations
with either lysate or peptide pulsed DCs. These results provide evidence for a strong Th1 po-
larization and cross-priming of MUC1 specific CTLs and demonstrate the feasibility of using
lysate-pulsed dendritic cells in breast cancer immunotherapy.
Chapter 7
Outlook
The development of the optimized protocol for the reproducible and serum-free generation of
fully mature dendritic cells provides the number of cells necessary for immunotherapeutical
vaccine strategies either cultivated in tissue culture flasks or hydrophobic teflon bags. Never-
theless, it would be useful to investigate the influence of different materials on the yield and
apoptosis induction to further improve the differentiation in a fully closed bag system.
The investigation of apoptosis of monocytes and their fate during differentiation gave new
insight in the process of the generation of dendritic cells. Further analysis of the influence of
cytokines with apoptosis inhibitor effects like IL-7 would be interesting.
A more detailed immunobiological analysis of dendritic cells is pivotal for understanding
of both the stimulatory and regulatory functions of lysate-pulsed dendritic cells. Therefore,
following in vitro experiments seem to have impact on the interplay of dendritic cells with the
immune system:
• A fully autologous system with T cells, dendritic cells and tumor cells from breast cancer
patients needs to be carried out with extensive analysis of the used tumor cells. For
expressed known tumor-associated antigens matching tetramers need to be utilized.
• For the tetramer analysis a broad spectrum of antigens would be useful, e.g. epitopes
from PLU-1, MUC1 and Her-2 / neu.
• Tetramer analysis of MHC class II specific T cells would give new insights in the activation
of T-helper cells by lysate-pulsed dendritic cells.
• A cytotox assay against primary tumor cells and tumor cell lines should be used to proove
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the cytotoxic functionality of activated T cells.
• A more detailed phenotypical analysis of stimulated T cells: Distinction between naive,
memory effector and regulatory T cells by using CD45RA, CD45RO and CCR7 expression
levels and specific cytokine staining for IFN-γ, IL-4, IL-10 and TGF-β.
• Investigation of Th1 type maturation stimuli, which induce the cytokine IL-12p70, on the
influence to result in migratory type dendritic cells.
Analysis of the glycoprotein MUC1 on the surface of mature dendritic cells demonstrated
expression of a normal, non breast cancer associated form of the protein (personal observation).
However, it would be useful to evaluate the influence on stimulation of T cells by non-aberrantly
glycosilated protein in comparison with the breast cancer related form. Additionally, it would
be of great interest to investigate whether aberrantly glycosilated MUC1 can be taken up
efficiently by dendritic cells.
Appendix A
Mathematical Calculations
Expansion Factor
Expansion factor =
Cell number dayx
Cell number day0
(A.1)
with:
dayx: day of sample
day0: day of inoculum
Growth Rate
The growth rate was determined using the following term:
µ =
ln(c2)− ln(c1)
$t (A.2)
with:
µ: Growth rate [ 1h ]
c1: Number of cells on day 0 or day of last sample
c2: Number of cells of sample 2
t1: Time of sample 1
t2: Time of sample 2
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Generation Time
The generation time was calculated using the following formula:
t =
ln2
µ
(A.3)
with:
t: Generation time [h]
µ: Growth rate [ 1h ]
Appendix B
Patient Information Sheet
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